Compounds for treating spinal muscular atrophy

ABSTRACT

The present invention provides compounds of formula (I) 
     
       
         
         
             
             
         
       
         
         
           
             wherein A, R 1 , R 2  and R 3  are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No.15/953,008, filed on Apr. 13, 2018, which is a continuation of U.S.patent application Ser. No. 15/351,267, filed on Nov. 14, 2016, now U.S.Pat. No. 9,969,754, issued on May 15, 2018, which is a continuation ofInternational Application No. PCT/EP2015/060343 having an Internationalfiling date of May 11, 2015, which claims the benefit of and priority toU.S. Provisional Application No. 61/993,839, filed on May 15, 2014, allof which are incorporated herein by reference in their entirety.

SEQUENCE LISTING

This application contains a Sequence Listing which has been submittedelectronically in ASCII format and is hereby incorporated by referencein its entirety. Said ASCII copy, created on Sep. 15, 2020, is namedP32010-US-4_SeqListing.txt and is 1,551 bytes in size.

INTRODUCTION

The present invention provides compounds which are SMN2 gene splicingmodulators, their manufacture, pharmaceutical compositions comprisingthem and their use as medicaments for the treatment of spinal muscularatrophy (SMA).

In particular, the present invention relates to compounds of formula (I)

wherein A, R¹, R² and R³ are as described herein, and pharmaceuticallyacceptable salts thereof.

BACKGROUND

Spinal muscular atrophy (SMA), in its broadest sense, describes acollection of inherited and acquired central nervous system (CNS)diseases characterized by progressive motor neuron loss in the spinalcord and brainstem causing muscle weakness and muscle atrophy. The mostcommon form of SMA is caused by mutations in the Survival Motor Neuron(SMN) gene and manifests over a wide range of severity affecting infantsthrough adults (Crawford and Pardo, Neurobiol. Dis., 1996, 3:97).

Infantile SMA is the most severe form of this neurodegenerativedisorder. Symptoms include muscle weakness, poor muscle tone, weak cry,limpness or a tendency to flop, difficulty sucking or swallowing,accumulation of secretions in the lungs or throat, feeding difficulties,and increased susceptibility to respiratory tract infections. The legstend to be weaker than the arms and developmental milestones, such aslifting the head or sitting up, cannot be reached. In general, theearlier the symptoms appear, the shorter the lifespan. As the motorneuron cells deteriorate, symptoms appear shortly afterward. The severeforms of the disease are fatal and all forms have no known cure. Thecourse of SMA is directly related to the rate of motor neuron celldeterioration and the resulting severity of weakness. Infants with asevere form of SMA frequently succumb to respiratory disease due toweakness in the muscles that support breathing. Children with milderforms of SMA live much longer, although they may need extensive medicalsupport, especially those at the more severe end of the spectrum. Theclinical spectrum of SMA disorders has been divided into the followingfive groups.

-   -   (a) Type 0 SMA (In Utero SMA) is the most severe form of the        disease and begins before birth. Usually, the first symptom of        Type 0 SMA is reduced movement of the fetus that can first be        observed between 30 and 36 weeks of pregnancy. After birth,        these newborns have little movement and have difficulties with        swallowing and breathing.    -   (b) Type 1 SMA (Infantile SMA or Werdnig-Hoffmann disease)        presents symptoms between 0 and 6 months, form of SMA is also        very severe. Patients never achieve the ability to sit, and        death usually occurs within the first 2 years without        ventilatory support.    -   (c) Type 2 SMA (Intermediate SMA) has an age of onset at 7-18        months. Patients achieve the ability to sit unsupported, but        never stand or walk unaided. Prognosis in this group is largely        dependent on the degree of respiratory involvement.    -   (d) Type 3 SMA (Juvenile SMA or Kugelberg-Welander disease) is        generally diagnosed after 18 months. Type 3 SMA individuals are        able to walk independently at some point during their disease        course but often become wheelchair-bound during youth or        adulthood.    -   (e) Type 4 SMA (Adult onset SMA). Weakness usually begins in        late adolescence in the tongue, hands, or feet, then progresses        to other areas of the body. The course of adult SMA is much        slower and has little or no impact on life expectancy.

The SMN gene has been mapped by linkage analysis to a complex region inchromosome 5q. In humans, this region contains an approximately 500thousand base pairs (kb) inverted duplication resulting in two nearlyidentical copies of the SMN gene. SMA is caused by an inactivatingmutation or deletion of the telomeric copy of the gene (SMN1) in bothchromosomes, resulting in the loss of SMN1 gene function. However, allpatients retain the centromeric copy of the gene (SMN2), and the copynumber of the SMN2 gene in SMA patients generally correlates inverselywith the disease severity; i.e., patients with less severe SMA have morecopies of SMN2. Nevertheless, SMN2 is unable to compensate completelyfor the loss of SMN1 function due to alternative splicing of exon 7caused by a translationally silent C to T mutation in exon 7. As aresult, the majority of transcripts produced from SMN2 lack exon 7 (A7SMN2), and encode a truncated SMN protein that has an impaired functionand is rapidly degraded.

The SMN protein is thought to play a role in RNA processing andmetabolism, having a well characterized function of mediating theassembly of a specific class of RNA-protein complexes termed snRNPs. SMNmay have other functions in motor neurons, however its role inpreventing the selective degeneration of motor neurons is not wellestablished.

In most cases, SMA is diagnosed based on clinical symptoms and by thepresence of at least one copy of the SMN1 gene test. However, inapproximately 5% of cases SMA is caused by mutation in genes other thanthe inactivation of SMN 1, some known and others not yet defined. Insome cases, when the SMN 1 gene test is not feasible or does not showany abnormality, other tests such as an electromyography (EMG) or musclebiopsy may be indicated.

Medical care for SMA patients at present is limited to supportivetherapy including respiratory, nutritional and rehabilitation care;there is no drug known to address the underlying cause of the disease.Current treatment for SMA consists of prevention and management of thesecondary effects of chronic motor unit loss. The major management issuein Type 1 SMA is the prevention and early treatment of pulmonaryproblems, which are the cause of death in the majority of the cases.While some infants afflicted with SMA grow to be adults, those with Type1 SMA have a life expectancy of less than two years.

Several mouse models of SMA have been developed. In particular, the SMNdelta exon 7 (Δ7 SMN) model (Le et al., Hum. Mol. Genet., 2005, 14:845)carries both the SMN2 gene and several copies of the Δ7 SMN2 cDNA andrecapitulates many of the phenotypic features of Type 1 SMA. The Δ7 SMNmodel can be used for both SMN2 expression studies as well as theevaluation of motor function and survival. The C/C-allele mouse model(Jackson Laboratory strain #008714, The Jackson Laboratory, Bar Harbor,Me.) provides a less severe SMA disease model, with mice having reducedlevels of both SMN2 full length (FL SMN2) mRNA and SMN protein. TheC/C-allele mouse phenotype has the SMN2 gene and a hybrid mSMN1-SMN2gene that undergoes alternative splicing, but does not have overt muscleweakness. The C/C-allele mouse model is used for SMN2 expressionstudies.

As a result of improved understanding of the genetic basis andpathophysiology of SMA, several strategies for treatment have beenexplored, but none have yet demonstrated success in the clinic.

Gene replacement of SMN1, using viral delivery vectors, and cellreplacement, using differentiated SMN1^(+/+) stem cells, havedemonstrated efficacy in animal models of SMA. More research is neededto determine the safety and immune response and to address therequirement for the initiation of treatment at the neonatal stage beforethese approaches can be applied to humans.

Correction of alternative splicing of SMN2 in cultured cells has alsobeen achieved using synthetic nucleic acids as therapeutic agents: (i)antisense oligonucleotides that target sequence elements in SMN2pre-mRNA and shift the outcome of the splicing reaction toward thegeneration of full length SMN2 mRNA (Passim et al., Sci. Transl. Med,2011, 3; 72ra18; and, Hua et al., Nature, 2011, 478:123) and (ii)trans-splicing RNA molecules that provide a fully functional RNAsequence that replace the mutant fragment during splicing and generate afull length SMN1 mRNA (Coady and Lorson, J Neurosci., 2010, 30:126).

Other approaches under exploration include searching for drugs thatincrease SMN levels, enhance residual SMN function, or compensate forits loss. Aminoglycosides have been shown to enhance expression of astabilized SMN protein produced from Δ7 SMN2 mRNA by promoting thetranslational read-through of the aberrant stop codon, but have poorcentral nervous system penetration and are toxic after repeat dosing.Chemotherapeutic agents, such as aclarubicin, have been shown toincrease SMN protein in cell culture; however, the toxicity profile ofthese drugs prohibits long-term use in SMA patients. Some drugs underclinical investigation for the treatment of SMA include transcriptionactivators such as histone deacetylase (“HDAC”) inhibitors (e.g.,butyrates, valproic acid, and hydroxyurea), and mRNA stabilizers (mRNAdecapping inhibitor RG3039 from Repligen), the goal being to increasethe amount of total RNA transcribed from the SMN2 gene. However, the useof the HDAC inhibitors or mRNA stabilizers does not address theunderlying cause of SMA and may result in a global increase intranscription and gene expression with potential safety problems inhumans.

In an alternative approach, neuroprotective agents such as Olesoximehave been chosen for investigation. Such strategies are not aimed at SMNfor the treatment of SMA, but instead are being explored to protect theSMN-deficient motor neurons from neurodegeneration.

A system designed for identifying compounds that increase the inclusionof exon 7 of SMN into RNA transcribed from the SMN2 gene and certainbenzooxazole and benzoisoxazole compounds identified thereby have beendescribed in International Patent Application WO2009/151546A1. A systemdesigned for identifying compounds that cause ribosomal frameshifting toproduce a stabilized SMN protein from Δ7 SMN2 mRNA and certainisoindolinone compounds identified thereby have been described inInternational Patent Applications WO2010/019236A1 and WO2013/119916A2.

Despite the progress made in understanding the genetic basis andpathophysiology of SMA, there remains a need to identify compounds thatalter the course of spinal muscular atrophy, one of the most devastatingchildhood neurological diseases.

DETAILED DESCRIPTION OF THE INVENTION

Unless otherwise defined, all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art to which this invention belongs. Although methods and materialssimilar or equivalent to those described herein can be used in thepractice or testing of the invention, suitable methods and materials aredescribed below.

All publications, patent applications, patents, and other referencesmentioned herein are incorporated by reference in their entirety.

The nomenclature used in this Application is based on IUPAC systematicnomenclature, unless indicated otherwise.

Any open valency appearing on a carbon, oxygen, sulfur or nitrogen atomin the structures herein indicates the presence of a hydrogen, unlessindicated otherwise.

The definitions described herein apply irrespective of whether the termsin question appear alone or in combination. It is contemplated that thedefinitions described herein can be appended to form chemically-relevantcombinations, such as e.g. “heterocycloalkylaryl”,“haloalkylheteroaryl”, “arylalkylheterocycloalkyl”, or “alkoxyalkyl”.The last member of the combination is the radical which is binding tothe rest of the molecule. The other members of the combination areattached to the binding radical in reversed order in respect of theliteral sequence, e.g. the combination amino-C₁₋₇-alkyl refers to aC₁₋₇-alkyl which is substituted by amino, or e.g. the combinationarylalkylheterocycloalkyl refers to a heterocycloalkyl-radical which issubstituted by an alkyl which is substituted by an aryl.

The term “moiety” refers to an atom or group of chemically bonded atomsthat is attached to another atom or molecule by one or more chemicalbonds thereby forming part of a molecule. For example, the variables A,R¹, R² and R³ of formula (I) refer to moieties that are attached to thecore structure of formula (I) by a covalent bond.

When indicating the number of substituents, the term “one or more”refers to the range from one substituent to the highest possible numberof substitution, i.e. replacement of one hydrogen up to replacement ofall hydrogens by substituents.

The term “optional” or “optionally” denotes that a subsequentlydescribed event or circumstance can but need not occur, and that thedescription includes instances where the event or circumstance occursand instances in which it does not.

The term “substituent” denotes an atom or a group of atoms replacing ahydrogen atom on the parent molecule.

The term “substituted” denotes that a specified group bears one or moresubstituents. Where any group can carry multiple substituents and avariety of possible substituents is provided, the substituents areindependently selected and need not to be the same. The term“unsubstituted” means that the specified group bears no substituents.The term “optionally substituted” means that the specified group isunsubstituted or substituted by one or more substituents, independentlychosen from the group of possible substituents. When indicating thenumber of substituents, the term “one or more” means from onesubstituent to the highest possible number of substitution, i.e.replacement of one hydrogen up to replacement of all hydrogens bysubstituents.

The terms “compound(s) of this invention” and “compound(s) of thepresent invention” refer to compounds as disclosed herein andstereoisomers, tautomers, solvates, and salts (e.g., pharmaceuticallyacceptable salts) thereof.

When the compounds of the invention are solids, it is understood bythose skilled in the art that these compounds, and their solvates andsalts, may exist in different solid forms, particularly differentcrystal forms, all of which are intended to be within the scope of thepresent invention and specified formulae.

The term “pharmaceutically acceptable salts” denotes salts which are notbiologically or otherwise undesirable. Pharmaceutically acceptable saltsinclude both acid and base addition salts.

The term “pharmaceutically acceptable acid addition salt” denotes thosepharmaceutically acceptable salts formed with inorganic acids such ashydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid,carbonic acid, phosphoric acid, and organic acids selected fromaliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic,carboxylic, and sulfonic classes of organic acids such as formic acid,acetic acid, propionic acid, glycolic acid, gluconic acid, lactic acid,pyruvic acid, oxalic acid, malic acid, maleic acid, maloneic acid,succinic acid, fumaric acid, tartaric acid, citric acid, aspartic acid,ascorbic acid, glutamic acid, anthranilic acid, benzoic acid, cinnamicacid, mandelic acid, embonic acid, phenylacetic acid, methanesulfonicacid, ethanesulfonic acid, p-toluenesulfonic acid, and salicyclic acid.

The term “pharmaceutically acceptable base addition salt” denotes thosepharmaceutically acceptable salts formed with an organic or inorganicbase. Examples of acceptable inorganic bases include sodium, potassium,ammonium, calcium, magnesium, iron, zinc, copper, manganese, andaluminum salts. Salts derived from pharmaceutically acceptable organicnontoxic bases includes salts of primary, secondary, and tertiaryamines, substituted amines including naturally occurring substitutedamines, cyclic amines and basic ion exchange resins, such asisopropylamine, trimethylamine, diethylamine, triethylamine,tripropylamine, ethanolamine, 2-diethylaminoethanol, trimethamine,dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine,hydrabamine, choline, betaine, ethylenediamine, glucosamine,methylglucamine, theobromine, purines, piperizine, piperidine,N-ethylpiperidine, and polyamine resins.

Stereochemical definitions and conventions used herein generally followS. P. Parker, Ed., McGraw-Hill Dictionary of Chemical Terms (1984)McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S.,“Stereochemistry of Organic Compounds”, John Wiley & Sons, Inc., NewYork, 1994. In describing an optically active compound, the prefixes Dand L, or R and S, are used to denote the absolute configuration of themolecule about its chiral center(s). The substituents attached to thechiral center under consideration are ranked in accordance with theSequence Rule of Cahn, Ingold and Prelog. (Cahn et al. Angew. Chem.Inter. Edit. 1966, 5, 385; errata 511). The prefixes D and L or (+) and(−) are employed to designate the sign of rotation of plane-polarizedlight by the compound, with (−) or L designating that the compound islevorotatory. A compound prefixed with (+) or D is dextrorotatory.

The term “chiral center” denotes a carbon atom bonded to fournonidentical substituents. The term “chiral” denotes the ability ofnon-superimposability with the mirror image, while the term “achiral”refers to embodiments which are superimposable with their mirror image.Chiral molecules are optically active, i.e., they have the ability torotate the plane of plane-polarized light.

Compounds of the present invention can have one or more chiral centersand can exist in the form of optically pure enantiomers, mixtures ofenantiomers such as, for example, racemates, optically purediastereoisomers, mixtures of diastereoisomers, diastereoisomericracemates or mixtures of diastereoisomeric racemates. Whenever a chiralcenter is present in a chemical structure, it is intended that allstereoisomers associated with that chiral center are encompassed by thepresent invention.

The terms “halo”, “halogen”, and “halide” are used interchangeablyherein and denote fluoro, chloro, bromo, or iodo. One particular exampleof halogen is fluoro.

The term “alkyl” denotes a monovalent linear or branched saturatedhydrocarbon group of 1 to 12 carbon atoms. In particular embodiments,alkyl has 1 to 7 carbon atoms, and in more particular embodiments 1 to 4carbon atoms. Examples of alkyl include methyl, ethyl, propyl,isopropyl, n-butyl, iso-butyl, sec-butyl, or tert-butyl. Particularexamples for alkyl are methyl and ethyl.

The term “haloalkyl” denotes an alkyl group wherein at least one of thehydrogen atoms of the alkyl group has been replaced by same or differenthalogen atoms, particularly fluoro atoms.

Examples of haloalkyl include monofluoro-, difluoro- ortrifluoro-methyl, -ethyl or -propyl, for example 3,3,3-trifluoropropyl,2-fluoroethyl, 2,2,2-trifluoroethyl, fluoromethyl, or trifluoromethyland the like. The term “perhaloalkyl” denotes an alkyl group where allhydrogen atoms of the alkyl group have been replaced by the same ordifferent halogen atoms.

The term “bicyclic ring system” denotes two rings which are fused toeach other via a common single or double bond (annelated bicyclic ringsystem), via a sequence of three or more common atoms (bridged bicyclicring system) or via a common single atom (spiro bicyclic ring system).Bicyclic ring systems can be saturated, partially unsaturated,unsaturated or aromatic. Bicyclic ring systems can comprise heteroatomsselected from N, O and S.

The term “cycloalkyl” denotes a saturated monocyclic or bicyclichydrocarbon group of 3 to 10 ring carbon atoms. In particularembodiments cycloalkyl denotes a monovalent saturated monocyclichydrocarbon group of 3 to 8 ring carbon atoms. Bicyclic means consistingof two saturated carbocycles having one or more carbon atoms in common.Particular cycloalkyl groups are monocyclic. Examples for monocycliccycloalkyl are cyclopropyl, cyclobutanyl, cyclopentyl, cyclohexyl orcycloheptyl. Examples for bicyclic cycloalkyl arebicyclo[2.2.1]heptanyl, or bicyclo[2.2.2]octanyl. One particular exampleof cycloalkyl is cyclopropyl.

The term “heterocycloalkyl” denotes a saturated or partly unsaturatedmono-, bi- or tricyclic ring system of 3 to 9 ring atoms, comprising 1,2, or 3 ring heteroatoms selected from N, O and S, the remaining ringatoms being carbon. In particular embodiments, heterocycloalkyl is amonovalent saturated monocyclic ring system of 4 to 7 ring atoms,comprising 1, 2, or 3 ring heteroatoms selected from N, O and S, theremaining ring atoms being carbon. Examples for monocyclic saturatedheterocycloalkyl are aziridinyl, oxiranyl, azetidinyl, oxetanyl,pyrrolidinyl, tetrahydrofuranyl, tetrahydro-thienyl, pyrazolidinyl,imidazolidinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl,piperidinyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperazinyl,morpholinyl, thiomorpholinyl, 1,1-dioxo-thiomorpholin-4-yl, azepanyl,diazepanyl, homopiperazinyl, or oxazepanyl. Examples for bicyclicsaturated heterocycloalkyl are 8-aza-bicyclo[3.2.1]octyl, quinuclidinyl,8-oxa-3-aza-bicyclo[3.2.1]octyl, 9-aza-bicyclo[3.3.1]nonyl,3-oxa-9-aza-bicyclo[3.3.1]nonyl, or 3-thia-9-aza-bicyclo[3.3.1]nonyl.Examples of a partly unsaturated heterocycloalkyl are dihydrofuryl,imidazolinyl, dihydro-oxazolyl, tetrahydro-pyridinyl, or dihydropyranyl.Particular examples of heterocycloalkyl are 1,4-diazepanyl,hexahydropyrrolo[1,2-a]pyrazinyl, piperidinyl, piperazinyl andpyrrolidinyl. More particular examples of heterocycloalkyl arehexahydropyrrolo[1,2-a]pyrazinyl and piperazinyl.

The term “N-heterocycloalkyl” denotes a heterocycloalkyl radicalcontaining at least one nitrogen ring atom and where the point ofattachment of the heterocycloalkyl radical to the rest of the moleculeis through a nitrogen ring atom. Particular examples ofN-heterocycloalkyl are 1,4-diazepanyl, hexahydropyrrolo[1,2-a]pyrazinyl,piperidinyl, piperazinyl and pyrrolidinyl. More particular examples ofN-heterocycloalkyl are hexahydropyrrolo[1,2-a]pyrazinyl and piperazinyl.

The term “basicity” in reference to a compound is expressed herein bythe negative decadic logarithm of the acidity constant of the conjugateacid (pKa=−log Ka). The larger the pKa of the conjugate acid, thestronger the base (pKa+pKb=14). In this application, an atom orfunctional group is denoted “basic” if it is suitable to accept a protonand if the calculated pKa of its conjugate acid is at least 7, moreparticularly if the calculated pKa of its conjugate acid is at least7.8, most particularly if the calculated pKa of its conjugate acid is atleast 8. pKa values were calculated in-silico as described in F.Milletti et al., J. Chem. Inf. Model (2007) 47:2172-2181.

The term “alkylene” denotes a linear saturated divalent hydrocarbongroup of 1 to 7 carbon atoms or a divalent branched saturatedhydrocarbon group of 3 to 7 carbon atoms. Examples of alkylene groupsinclude methylene, ethylene, propylene, 2-methylpropylene, butylene,2-ethylbutylene, pentylene, hexylene. Particular examples for alkyleneare ethylene, propylene, and butylene.

The term “amino” denotes a group of the formula —NR′R″ wherein R′ and R″are independently hydrogen, alkyl, alkoxy, cycloalkyl, heterocycloalkyl,aryl, heteroaryl or as described herein. Alternatively, R′ and R″,together with the nitrogen to which they are attached, can form aheterocycloalkyl. The term “primary amino” denotes a group wherein bothR′ and R″ are hydrogen. The term “secondary amino” denotes a groupwherein R′ is hydrogen and R″ is a group other than hydrogen. The term“tertiary amino” denotes a group wherein both R′ and R″ are other thanhydrogen. Particular secondary and tertiary amines are methylamine,ethylamine, propylamine, isopropylamine, phenylamine, benzylaminedimethylamine, diethylamine, dipropylamine and diisopropylamine.

The term “active pharmaceutical ingredient” (or “API”) denotes thecompound or molecule in a pharmaceutical composition that has aparticular biological activity.

The terms “pharmaceutical composition” and “pharmaceutical formulation”(or “formulation”) are used interchangeably and denote a mixture orsolution comprising a therapeutically effective amount of an activepharmaceutical ingredient together with pharmaceutically acceptableexcipients to be administered to a mammal, e.g., a human in needthereof.

The term “pharmaceutically acceptable” denotes an attribute of amaterial which is useful in preparing a pharmaceutical composition thatis generally safe, non-toxic, and neither biologically nor otherwiseundesirable and is acceptable for veterinary as well as humanpharmaceutical use.

The terms “pharmaceutically acceptable excipient”, “pharmaceuticallyacceptable carrier” and “therapeutically inert excipient” can be usedinterchangeably and denote any pharmaceutically acceptable ingredient ina pharmaceutical composition having no therapeutic activity and beingnon-toxic to the subject administered, such as disintegrators, binders,fillers, solvents, buffers, tonicity agents, stabilizers, antioxidants,surfactants, carriers, diluents or lubricants used in formulatingpharmaceutical products.

The terms “individual” or “subject” refer to a mammal. Mammals include,but are not limited to, domesticated animals (e.g., cows, sheep, cats,dogs, and horses), primates (e.g., humans and non-human primates such asmonkeys), rabbits, and rodents (e.g., mice and rats). In certainembodiments, the individual or subject is a human.

The term “therapeutically effective amount” denotes an amount of acompound or molecule of the present invention that, when administered toa subject, (i) treats or prevents the particular disease, condition ordisorder, (ii) attenuates, ameliorates or eliminates one or moresymptoms of the particular disease, condition, or disorder, or (iii)prevents or delays the onset of one or more symptoms of the particulardisease, condition or disorder described herein. The therapeuticallyeffective amount will vary depending on the compound, the disease statebeing treated, the severity of the disease treated, the age and relativehealth of the subject, the route and form of administration, thejudgement of the attending medical or veterinary practitioner, and otherfactors.

The terms “treating” or “treatment” of a disease state includeinhibiting the disease state, i.e., arresting the development of thedisease state or its clinical symptoms, or relieving the disease state,i.e., causing temporary or permanent regression of the disease state orits clinical symptoms.

The term “spinal muscular atrophy” (or SMA) relates to a disease causedby an inactivating mutation or deletion in the SMN1 gene on bothchromosomes, resulting in a loss of SMN1 gene function.

Symptoms of SMA include muscle weakness, poor muscle tone, weak cry,weak cough, limpness or a tendency to flop, difficulty sucking orswallowing, difficulty breathing, accumulation of secretions in thelungs or throat, clenched fists with sweaty hand, flickering/vibratingof the tongue, head often tilted to one side, even when lying down, legsthat tend to be weaker than the arms, legs frequently assuming a “froglegs” position, feeding difficulties, increased susceptibility torespiratory tract infections, bowel/bladder weakness, lower-than-normalweight, inability to sit without support, failure to walk, failure tocrawl, and hypotonia, areflexia, and multiple congenital contractures(arthrogryposis) associated with loss of anterior horn cells.

The term “treating spinal muscular atrophy (SMA)” or “treatment ofspinal muscular atrophy (SMA)” includes one or more of the followingeffects: (i) reduction or amelioration of the severity of SMA; (ii)delay of the onset of SMA; (iii) inhibition of the progression of SMA;(iv) reduction of hospitalization of a subject; (v) reduction ofhospitalization length for a subject; (vi) increase of the survival of asubject; (vii) improvement of the quality of life of a subject; (viii)reduction of the number of symptoms associated with SMA; (ix) reductionof or amelioration of the severity of one or more symptoms associatedwith SMA; (x) reduction of the duration of a symptom associated withSMA; (xi) prevention of the recurrence of a symptom associated with SMA;(xii) inhibition of the development or onset of a symptom of SMA; and/or(xiii) inhibition of the progression of a symptom associated with SMA.

More particular, the term “treating SMA” denotes one or more of thefollowing beneficial effects: (i) a reduction in the loss of musclestrength; (ii) an increase in muscle strength; (iii) a reduction inmuscle atrophy; (iv) a reduction in the loss of motor function; (v) anincrease in motor neurons; (vii) a reduction in the loss of motorneurons; (viii) protection of SMN deficient motor neurons fromdegeneration; (ix) an increase in motor function; (x) an increase inpulmonary function; and/or (xi) a reduction in the loss of pulmonaryfunction. In further detail, the term “treating SMA” refers to thefunctional ability or retention of the functional ability for a humaninfant or a human toddler to sit up unaided or for a human infant, ahuman toddler, a human child or a human adult to stand up unaided, towalk unaided, to run unaided, to breathe unaided, to turn during sleepunaided, or to swallow unaided.

The term “EC_(1.5x) concentration for production of full length SMN2minigene mRNA” (or “EC_(1.5x) minigene”) is defined as thatconcentration of test compound that 1 s effective m increasing theamount of full length SMN2 minigene mRNA to a level 1.5-fold greaterrelative to that in vehicle-treated cells.

The term “EC_(1.5x) concentration for SMN protein expression” (or“EC_(1.5x) SMN protein”) is defined as that concentration of testcompound that is effective in producing 1.5 times the amount of SMNprotein in an SMA patient fibroblast cell compared to the amountproduced from the vehicle control.

In detail, the present invention relates to compounds of formula (I)

wherein

-   -   R¹ is hydrogen or C₁₋₇-alkyl;    -   R² is hydrogen, cyano, C₁₋₇-alkyl, C₁₋₇-haloalkyl or        C₃₋₈-cycloalkyl;    -   R³ is hydrogen, C₁₋₇-alkyl, or C₃₋₈-cycloalkyl;    -   A is N-heterocycloalkyl or NR¹²R¹³, wherein N-heterocycloalkyl        comprises 1 or 2 nitrogen ring atoms and is optionally        substituted with 1, 2, 3 or 4 substituents selected from R¹⁴;    -   R¹² is heterocycloalkyl comprising 1 nitrogen ring atom, wherein        heterocycloalkyl is optionally substituted with 1, 2, 3 or 4        substituents selected from R¹⁴;    -   R¹³ is hydrogen, C₁₋₇-alkyl or C₃₋₈-cycloalkyl;    -   R¹⁴ is independently selected from hydrogen, C₁₋₇-alkyl, amino,        amino-C₁₋₇-alkyl, C₃₋₈-cycloalkyl and heterocycloalkyl or two        R¹⁴ together form C₁₋₇-alkylene;    -   with the proviso that if A is N-heterocycloalkyl comprising only        1 nitrogen ring atom, then at least one R¹⁴ substituent is amino        or amino-C₁₋₇-alkyl;    -   and pharmaceutically acceptable salts thereof.

Particular embodiments of the present invention are compounds of formula(I) and pharmaceutically acceptable salts thereof.

Further, it is to be understood that every embodiment relating to aspecific A, R¹, R² or R³ as disclosed herein may be combined with anyother embodiment relating to another A, R¹, R² or R³ as disclosedherein.

A particular embodiment of the present invention relates to compounds offormula (I) wherein

-   -   R¹ is hydrogen or C₁₋₇-alkyl;    -   R² is hydrogen, cyano, C₁₋₇-alkyl, C₁₋₇-haloalkyl or        C₃₋₈-cycloalkyl;    -   R³ is hydrogen, C₁₋₇-alkyl, or C₃₋₈-cycloalkyl;    -   A is N-heterocycloalkyl comprising 1 or 2 nitrogen ring atoms,        wherein N-heterocycloalkyl is optionally substituted with 1, 2,        3 or 4 substituents selected from R¹⁴;    -   R¹⁴ is independently selected from hydrogen, C₁₋₇-alkyl, amino,        amino-C₁₋₇-alkyl, C₃₋₈-cycloalkyl and heterocycloalkyl or two        R¹⁴ together form C₁₋₇-alkylene;    -   with the proviso that if A is N-heterocycloalkyl comprising only        1 nitrogen ring atom, then at least one R¹⁴ substituent is amino        or amino-C₁₋₇-alkyl;    -   and pharmaceutically acceptable salts thereof.

A particular embodiment of the present invention relates to compounds offormula (I), wherein R¹ is C₁₋₇-alkyl, particularly methyl.

A particular embodiment of the present invention relates to compounds offormula (I), wherein R² is hydrogen or C₁₋₇-alkyl, particularly hydrogenor methyl.

A particular embodiment of the present invention relates to compounds offormula (I), wherein R³ is hydrogen or C₁₋₇-alkyl, particularly hydrogenor methyl.

A particular embodiment of the present invention relates to compounds offormula (I), wherein R¹² is piperidinyl optionally substituted with 1,2, 3 or 4 substituents selected from R¹⁴.

A particular embodiment of the present invention relates to compounds offormula (I), wherein R¹³ is hydrogen or C₁₋₇-alkyl, particularlyhydrogen or methyl.

A particular embodiment of the present invention relates to compounds offormula (I), wherein R¹⁴ is independently selected from C₁₋₇-alkyl andheterocycloalkyl or two R¹⁴ together form C₁₋₇-alkylene.

A particular embodiment of the present invention relates to compounds offormula (I), wherein R¹⁴ is independently selected from methyl, ethyland pyrrolidinyl or two R¹⁴ together form ethylene.

A particular embodiment of the present invention relates to compounds offormula (I), wherein A is a saturated mono- or bicyclicN-heterocycloalkyl comprising 1 or 2 nitrogen atoms and is optionallysubstituted with 1, 2, 3 or 4 substituents selected from R¹⁴.

A particular embodiment of the present invention relates to compounds offormula (I), wherein the N-heterocycloalkyl in A or the heterocycloalkylin R¹² as defined herein are substituted with 1 or 2 substituentsselected from R¹⁴.

A particular embodiment of the present invention relates to compounds offormula (I), wherein the N-heterocycloalkyl in A as defined herein isfurther characterized in that one ring nitrogen atoms is basic.

A particular embodiment of the present invention relates to compounds offormula (I), wherein A is

wherein

-   -   X is N or CH;    -   R⁴ is hydrogen, C₁₋₇-alkyl or —(CH₂)_(m)—NR⁹R¹⁰;    -   R⁵ is hydrogen or C₁₋₇-alkyl;    -   R⁶ is hydrogen or C₁₋₇-alkyl;    -   R⁷ is hydrogen or C₁₋₇-alkyl;    -   R⁸ is hydrogen or C₁₋₇-alkyl;    -   R⁹ and R¹⁰ are independently selected from hydrogen, C₁₋₇-alkyl        and C₃₋₈-cycloalkyl;    -   R¹³ is hydrogen, C₁₋₇-alkyl or C₃₋₈-cycloalkyl;    -   n is 0, 1 or 2;    -   m is 0, 1, 2 or 3;    -   or R⁴ and R⁵ together form a C₁₋₇-alkylene;    -   or R⁴ and R⁷ together form a C₁₋₇-alkylene;    -   or R⁵ and R⁶ together form a C₂₋₇-alkylene;    -   or R⁵ and R⁷ together form a C₁₋₇-alkylene;    -   or R⁵ and R⁹ together form a C₁₋₇-alkylene;    -   or R⁷ and R⁸ together form a C₂₋₇-alkylene;    -   or R⁷ and R⁹ together form a C₁₋₇-alkylene;    -   or R⁹ and R¹⁰ together form a C₂₋₇-alkylene;    -   with the proviso that if X is CH then R⁴ is —(CH₂)_(m)—NR⁹R¹⁰;        and    -   with the proviso that if X is N and R⁴ is —(CH₂)_(m)—NR⁹R¹⁰ then        m is 2 or 3.

A particular embodiment of the present invention relates to compounds offormula (I), wherein A is

wherein

-   -   X is N or CH;    -   R⁴ is hydrogen, C₁₋₇-alkyl or —(CH₂)_(m)—NR⁹R¹⁰;    -   R⁵ is hydrogen or C₁₋₇-alkyl;    -   R⁶ is hydrogen or C₁₋₇-alkyl;    -   R⁷ is hydrogen or C₁₋₇-alkyl;    -   R⁸ is hydrogen or C₁₋₇-alkyl;    -   R⁹ and R¹⁰ are independently selected from hydrogen, C₁₋₇-alkyl        and C₃₋₈-cycloalkyl;    -   n is 0, 1 or 2;    -   m is 0, 1, 2 or 3;    -   or R⁴ and R⁵ together form C₁₋₇-alkylene;    -   or R⁴ and R⁷ together form C₁₋₇-alkylene;    -   or R⁵ and R⁶ together form C₂₋₇-alkylene;    -   or R⁵ and R⁷ together form C₁₋₇-alkylene;    -   or R⁵ and R⁹ together form C₁₋₇-alkylene;    -   or R⁷ and R⁸ together form C₂₋₇-alkylene;    -   or R⁷ and R⁹ together form C₁₋₇-alkylene;    -   or R⁹ and R¹⁰ together form C₂₋₇-alkylene;    -   with the proviso that if X is CH then R⁴ is —(CH₂)_(m)—NR⁹R¹⁰;        and    -   with the proviso that if X is N and R⁴ is —(CH₂)_(m)—NR⁹R¹⁰ then        m is 2 or 3.

It has been found that brain penetration is improved when at least oneof R⁴, R⁵, R⁶, R⁷ and R⁸ is not hydrogen.

In a particular embodiment of the invention at least one of R⁴, R⁵, R⁶,R⁷ and R⁸ is other than hydrogen.

A particular embodiment of the present invention relates to compounds offormula (I), wherein X is N.

A particular embodiment of the present invention relates to compounds offormula (I), wherein n is 1.

A particular embodiment of the present invention relates to compounds offormula (I), wherein R⁴ is hydrogen, methyl or —(CH₂)_(m)—NR⁹R¹⁰, moreparticularly hydrogen.

A particular embodiment of the present invention relates to compounds offormula (I), wherein R⁵ is hydrogen, methyl or ethyl, more particularlymethyl.

A particular embodiment of the present invention relates to compounds offormula (I), wherein R⁶ is hydrogen or methyl, more particularlyhydrogen.

A particular embodiment of the present invention relates to compounds offormula (I), wherein R⁷ is hydrogen or methyl.

A particular embodiment of the present invention relates to compounds offormula (I), wherein R⁸ is hydrogen.

A particular embodiment of the present invention relates to compounds offormula (I), wherein m is 0.

A particular embodiment of the present invention relates to compounds offormula (I), wherein R⁴ and R⁵ together form propylene.

A particular embodiment of the present invention relates to compounds offormula (I), wherein R⁵ and R⁶ together form ethylene;

A particular embodiment of the present invention relates to compounds offormula (I), wherein R⁹ and R¹⁰ together form butylene.

A particular embodiment of the present invention relates to compounds offormula (I), wherein A is selected from the group of:

wherein R⁴, R⁵, R⁶, R⁷, R⁸ and R¹³ are as defined herein and wherein R¹¹is hydrogen or C₁₋₇-alkyl.

A particular embodiment of the present invention relates to compounds offormula (I), wherein A is selected from the group of:

wherein R⁴, R⁵, R⁶, R⁷ and R⁸ are as defined herein and wherein R¹¹ ishydrogen or C₁₋₇-alkyl.

A particular embodiment of the present invention relates to compounds offormula (I), wherein A is selected from the group of piperazinyl,diazepanyl, pyrrolidinyl and hexahydropyrrolo[1,2-a]pyrazinyl, eachoptionally substituted with 1, 2, 3 or 4 substituents selected from R¹⁴as defined herein.

A particular embodiment of the present invention relates to compounds offormula (I), wherein A is selected from the group of piperazin-1-yl,1,4-diazepan-1-yl, pyrrolidin-1-yl andhexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl, each optionally substitutedwith 1 or 2 substituents selected from R¹⁴ as defined herein.

A particular embodiment of the present invention relates to compounds offormula (I), wherein A is NR¹²R¹³, wherein R¹² and R¹³ are as describedherein.

A particular embodiment of the present invention relates to compounds offormula (I), wherein A is

wherein R⁴, R⁵, R⁶, R⁷, R⁸ and R¹³ are as described herein.

A particular embodiment of the present invention relates to compounds offormula (I), wherein A is

wherein R¹³ is hydrogen or methyl.

A particular embodiment of the present invention relates to compounds offormula (I), wherein A is selected from the group of:

A particular embodiment of the present invention relates to compounds offormula (I), wherein A is selected from the group of:

Particular compounds of formula (I) of the present invention are thoseselected from the group consisting of:

-   2-(2-methylimidazo[1,2-b]pyridazin-6-yl)-7-(4-methylpiperazin-1-yl)pyrido[1,2-a]pyrimidin-4-one;-   7-[(8aR)-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazin-2-yl]-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one;-   7-[(8aS)-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazin-2-yl]-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one;-   7-[(8aR)-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazin-2-yl]-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one;-   7-[(8aS)-8a-methyl-1,3,4,6,7,8-hexahydropyrrolo[1,2-a]pyrazin-2-yl]-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one;-   7-[(8aR)-8a-methyl-1,3,4,6,7,8-hexahydropyrrolo[1,2-a]pyrazin-2-yl]-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one;-   2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-[(3S,5R)-3,5-dimethylpiperazin-1-yl]pyrido[1,2-a]pyrimidin-4-one;-   2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-[(3S)-3-methylpiperazin-1-yl]pyrido[1,2-a]pyrimidin-4-one;-   2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-[(3R)-3-methylpiperazin-1-yl]pyrido[1,2-a]pyrimidin-4-one;-   7-(1,4-diazepan-1-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one;-   2-(2-methylimidazo[1,2-b]pyridazin-6-yl)-7-[(3S)-3-methylpiperazin-1-yl]pyrido[1,2-a]pyrimidin-4-one;-   2-(2-methylimidazo[1,2-b]pyridazin-6-yl)-7-[(3R)-3-methylpiperazin-1-yl]pyrido[1,2-a]pyrimidin-4-one;-   7-(1,4-diazepan-1-yl)-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one;-   7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one;-   7-[(8aS)-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazin-2-yl]-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one;-   7-[(8aS)-8a-methyl-1,3,4,6,7,8-hexahydropyrrolo[1,2-a]pyrazin-2-yl]-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one;-   7-[(8aR)-8a-methyl-1,3,4,6,7,8-hexahydropyrrolo[1,2-a]pyrazin-2-yl]-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one;-   2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-[(3R)-3-pyrrolidin-1-ylpyrrolidin-1-yl]pyrido[1,2-a]pyrimidin-4-one;-   7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one;-   7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one;-   2-(2-methylimidazo[1,2-b]pyridazin-6-yl)-7-[(3R)-3-pyrrolidin-1-ylpyrrolidin-1-yl]pyrido[1,2-a]pyrimidin-4-one;-   2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-(3,3-dimethylpiperazin-1-yl)pyrido[1,2-a]pyrimidin-4-one;-   7-(3,3-dimethylpiperazin-1-yl)-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one;-   2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-9-methyl-7-[(3S)-3-methylpiperazin-1-yl]pyrido[1,2-a]pyrimidin-4-one;-   2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-9-methyl-7-[(3R)-3-methylpiperazin-1-yl]pyrido[1,2-a]pyrimidin-4-one;-   2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-9-methyl-pyrido[1,2-a]pyrimidin-4-one;-   2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-(3,3-dimethylpiperazin-1-yl)-9-methyl-pyrido[1,2-a]pyrimidin-4-one;-   7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-9-methyl-pyrido[1,2-a]pyrimidin-4-one;-   2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-[(3S,5S)-3,5-dimethylpiperazin-1-yl]pyrido[1,2-a]pyrimidin-4-one;-   2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-[(3S)-3-pyrrolidin-1-ylpyrrolidin-1-yl]pyrido[1,2-a]pyrimidin-4-one;-   2-(2-methylimidazo[1,2-b]pyridazin-6-yl)-7-[(3S)-3-pyrrolidin-1-ylpyrrolidin-1-yl]pyrido[1,2-a]pyrimidin-4-one;-   7-[(3S,5S)-3,5-dimethylpiperazin-1-yl]-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one;-   9-methyl-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)-7-[(3S)-3-methylpiperazin-1-yl]pyrido[1,2-a]pyrimidin-4-one;-   9-methyl-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)-7-[(3R)-3-methylpiperazin-1-yl]pyrido[1,2-a]pyrimidin-4-one;-   7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-9-methyl-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one;-   7-(3,3-dimethylpiperazin-1-yl)-9-methyl-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one;-   7-(4,7-diazaspiro[2.5]octan-7-yl)-9-methyl-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one;-   7-[(3S,5S)-3,5-dimethylpiperazin-1-yl]-9-methyl-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one;-   7-[(3R)-3-ethylpiperazin-1-yl]-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one;    and pharmaceutically acceptable salts thereof.

Particular compounds of formula (I) of the present invention are thoseselected from the group consisting of:

-   7-[(8aR)-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazin-2-yl]-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one;-   7-[(8aS)-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazin-2-yl]-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one;-   7-[(8aR)-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazin-2-yl]-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one;-   2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-[(3S,5R)-3,5-dimethylpiperazin-1-yl]pyrido[1,2-a]pyrimidin-4-one;-   7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one;-   7-[(8aS)-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazin-2-yl]-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one;-   7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one;-   7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one;-   2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-9-methyl-7-[(3S)-3-methylpiperazin-1-yl]pyrido[1,2-a]pyrimidin-4-one;-   7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-9-methyl-pyrido[1,2-a]pyrimidin-4-one;-   7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-9-methyl-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one;-   7-(4,7-diazaspiro[2.5]octan-7-yl)-9-methyl-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one;    and pharmaceutically acceptable salts thereof.

Compounds of formula (VI) are suitable as intermediates in themanufacture of compounds of formula (I).

Another embodiment of the invention relates to compounds of formula (VI)

wherein R¹, R² and R³ are as described herein;

Y is halogen or trifluoromethanesulfonate;

and salts thereof.

A particular embodiment of the present invention relates to compounds offormula (VI), wherein Y is fluoro, chloro, bromo, iodo ortrifluoromethanesulfonate, particularly fluoro.

Particular compounds of formula (VI) of the present invention are thoseselected from the group consisting of:

-   7-fluoro-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one;-   2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-fluoro-pyrido[1,2-a]pyrimidin-4-one;-   7-fluoro-9-methyl-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one;-   2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-fluoro-9-methyl-pyrido[1,2-a]pyrimidin-4-one;    and salts thereof.

Manufacturing Processes

Compounds of formula (I) and pharmaceutically acceptable salts thereofas defined above can be prepared following standard methods known in theart.

As illustrated in Scheme 1, the commercially available amino-pyridine offormula (II) can be reacted with a malonic ester to afford theintermediate of formula (III), wherein Y and R³ are as described hereinand R is C₁₋₂-alkyl, particularly methyl. The compound of formula (III)is then treated with a chlorinating reagent (such as POCl₃ and the like)to provide a compound of formula (IV). The compound of formula (IV) isthen reacted in a Suzuki cross-coupling reaction with a compound offormula (V), wherein R¹ and R² are as described herein and Z is B(OH)₂or an C₁₋₇-alkyl boronic acid ester such as4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl, in the presence of acatalyst (such as (1,1′-bis(diphenylphosphino)ferrocene)palladium(II)dichloride (Pd(dppf)Cl₂) and the like) and a base (such as K₂CO₃ and thelike) in a suitable solvent (such as DMF and the like), to afford thecompound of formula (VI). Finally, the compound of formula (VI) isreacted with a compound M-A either in:

-   -   a) an aromatic nucleophilic substitution reaction (particularly        if Y is fluoro) by heating at a temperature from 80° C. to 200°        C.; or    -   b) a Buchwald-Hartwig amination reaction in the presence of a        palladium catalyst (e.g. tetrakis(triphenylphosphine)palladium        (Pd(PPh₃)₄) or bis(dibenzylideneacetone)palladium (Pd(dba)₂) by        heating at a temperature from 20° C. to 100° C.;

in a solvent (e.g. dimethyl sulfoxide (DMSO), N-methylpyrrolidone (NMP),or dimethylformamide (DMF)) to give a compound of formula (I), wherein Ais as defined herein, M is hydrogen, sodium or potassium, particularlyhydrogen, and wherein M is linked to A via a nitrogen atom of A.

In one embodiment, the invention relates to a process for themanufacture of compounds of formula (I) and pharmaceutically acceptablesalts thereof as defined above, comprising the reaction of a compound offormula (VI) with a compound M-A either in:

-   -   a) an aromatic nucleophilic substitution reaction (particularly        if Y is fluoro) by heating at a temperature from 80° C. to 200°        C.; or    -   b) a Buchwald-Hartwig amination reaction in the presence of a        palladium catalyst (e.g. tetrakis(triphenylphosphine)palladium        (Pd(PPh₃)₄) or bis(dibenzylideneacetone)palladium Pd(dba)₂) by        heating at a temperature from 20° C. to 100° C.;

in a solvent (e.g. dimethyl sulfoxide (DMSO), N-methylpyrrolidone (NMP),or dimethylformamide (DMF)), wherein A, Y, R¹, R² and R³ are as definedherein, M is hydrogen, sodium or potassium, particularly hydrogen, andwherein M is linked to A via a nitrogen atom of A.

A particular embodiment of the invention relates to a process for thepreparation of compounds of formula (I) and pharmaceutically acceptablesalts thereof as defined above, comprising an aromatic nucleophilicsubstitution reaction between a compound of formula (VI) as describedabove with a compound of formula M-A by heating in a solvent, wherein A,R¹, R², R³ and Y are as defined above, M is hydrogen, sodium orpotassium, and wherein M is linked to A via a nitrogen atom of A.

A particular embodiment of the invention relates to a process for thepreparation of compounds of formula (I) and pharmaceutically acceptablesalts thereof as defined above, wherein the aromatic nucleophilicsubstitution reaction is performed at a temperature from 80° C. to 200°C.

A particular embodiment of the invention relates to a process for thepreparation of compounds of formula (I) and pharmaceutically acceptablesalts thereof as defined above, wherein the solvent of the aromaticnucleophilic substitution reaction is selected from dimethyl sulfoxide(DMSO), N-methylpyrrolidone (NMP), and dimethylformamide (DMF).

A particular embodiment of the invention relates to a process for thepreparation of compounds of formula (I) and pharmaceutically acceptablesalts thereof as defined above, wherein M is hydrogen.

Particularly, compounds of formula (I) and pharmaceutically acceptablesalts thereof can be prepared in accordance to the methods described inthe examples herein.

Pharmaceutical Compositions

Another embodiment provides pharmaceutical compositions or medicamentscomprising the compounds of the invention and a therapeutically inertcarrier, diluent or pharmaceutically acceptable excipient, as well asmethods of using the compounds of the invention to prepare suchcompositions and medicaments.

Compositions are formulated, dosed, and administered in a fashionconsistent with good medical practice. Factors for consideration in thiscontext include the particular disorder being treated, the particularmammal being treated, the clinical condition of the individual patient,the cause of the disorder, the site of delivery of the agent, the methodof administration, the scheduling of administration, and other factorsknown to medical practitioners.

The compounds of the invention may be administered by any suitablemeans, including oral, topical (including buccal and sublingual),rectal, vaginal, transdermal, parenteral, subcutaneous, intraperitoneal,intrapulmonary, intradermal, intrathecal and epidural and intranasal,and, if desired for local treatment, intralesional administration.Parenteral infusions include intramuscular, intravenous, intraarterial,intraperitoneal, or subcutaneous administration.

The compounds of the present invention may be administered in anyconvenient administrative form, e.g., tablets, powders, capsules,solutions, dispersions, suspensions, syrups, sprays, suppositories,gels, emulsions, patches, etc. Such compositions may comprise componentsconventional in pharmaceutical preparations, e.g., diluents, carriers,pH modifiers, preservatives, solubilizers, stabilizers, wetting agents,emulsifiers, sweeteners, colorants, flavorants, salts for varying theosmotic pressure, buffers, masking agents, antioxidants, and furtheractive agents. They can also comprise still other therapeuticallyvaluable substances.

A typical formulation is prepared by mixing a compound of the presentinvention and a carrier or excipient. Suitable carriers and excipientsare well known to those skilled in the art and are described in detailin, e.g., Ansel H. C. et al., Ansel's Pharmaceutical Dosage Forms andDrug Delivery Systems (2004) Lippincott, Williams & Wilkins,Philadelphia; Gennaro A. R et al., Remington; The Science and Practiceof Pharmacy (2000) Lippincott, Williams & Wilkins, Philadelphia; andRowe R. C, Handbook of Pharmaceutical Excipients (2005) PharmaceuticalPress, Chicago. The formulations may also include one or more buffers,stabilizing agents, surfactants, wetting agents, lubricating agents,emulsifiers, suspending agents, preservatives, antioxidants, opaquingagents, glidants, processing aids, colorants, sweeteners, perfumingagents, flavoring agents, diluents and other known additives to providean elegant presentation of the drug (i.e., a compound of the presentinvention or pharmaceutical composition thereof) or aid in themanufacturing of the pharmaceutical product (i.e., medicament).

The dosage at which compounds of the invention can be administered canvary within wide limits and will, of course, be fitted to the individualrequirements in each particular case. In general, in the case of oraladministration a daily dosage of about 0.01 to 1000 mg per person of acompound of general formula (I) should be appropriate, although theabove upper limit can also be exceeded when necessary.

An example of a suitable oral dosage form is a tablet comprising about100 mg to 500 mg of the compound of the invention compounded with about30 to 90 mg anhydrous lactose, about 5 to 40 mg sodium croscarmellose,about 5 to 30 mg polyvinylpyrrolidone (PVP) K30, and about 1 to 10 mgmagnesium stearate. The powdered ingredients are first mixed togetherand then mixed with a solution of the PVP. The resulting composition canbe dried, granulated, mixed with the magnesium stearate and compressedto tablet form using conventional equipment.

An example of an aerosol formulation can be prepared by dissolving thecompound, for example 10 to 100 mg, of the invention in a suitablebuffer solution, e.g. a phosphate buffer, adding a tonicifier, e.g. asalt such as sodium chloride, if desired. The solution may be filtered,e.g., using a 0.2 μm filter, to remove impurities and contaminants.

Uses

As described above, the compounds of formula (I) and theirpharmaceutically acceptable salts possess valuable pharmacologicalproperties and have been found to enhance inclusion of exon 7 of SMN1and/or SMN2 into mRNA transcribed from the SMN1 and/or SMN2 gene,thereby increasing expression of SMN protein in a human subject in needthereof.

The compounds of the present invention can be used, either alone or incombination with other drugs, for the treatment or prevention ofdiseases caused by an inactivating mutation or deletion in the SMN1 geneand/or associated with loss or defect of SMN1 gene function. Thesediseases include, but are not limited to spinal muscular atrophy (SMA).

A particular embodiment of the present invention relates topharmaceutical compositions comprising compounds of formula (I) asdefined above or their pharmaceutically acceptable salts as definedabove and one or more pharmaceutically acceptable excipients.

A particular embodiment of the present invention relates topharmaceutical compositions comprising compounds of formula (I) or theirpharmaceutically acceptable salts as defined above and one or morepharmaceutically acceptable excipients for the treatment or preventionof diseases caused by an inactivating mutation or deletion in the SMN1gene and/or associated with loss or defect of SMN1 gene function,particularly for the treatment or prevention of SMA.

A particular embodiment of the present invention relates to compounds offormula (I) or their pharmaceutically acceptable salts as defined abovefor use as therapeutically active substances, especially for use astherapeutically active substances for the treatment or prevention ofdiseases caused by an inactivating mutation or deletion in the SMN1 geneand/or associated with loss or defect of SMN1 gene function,particularly for the treatment or prevention of spinal muscular atrophy(SMA).

A particular embodiment of the present invention relates to compounds offormula (I) or their pharmaceutically acceptable salts as defined abovefor the use in the treatment or prevention of diseases caused by aninactivating mutation or deletion in the SMN1 gene and/or associatedwith loss or defect of SMN1 gene function, particularly for use in thetreatment or prevention of spinal muscular atrophy (SMA).

A particular embodiment of the present invention relates to a method forthe treatment or prevention of diseases caused by an inactivatingmutation or deletion in the SMN1 gene and/or associated with loss ordefect of SMN1 gene function, particularly for the treatment orprevention of spinal muscular atrophy (SMA), which method comprisesadministering compounds of formula (I) or their pharmaceuticallyacceptable salts as defined above to a subject.

A particular embodiment of the present invention relates to the use ofcompounds of formula (I) or their pharmaceutically acceptable salts asdefined above for the treatment or prevention of diseases caused by aninactivating mutation or deletion in the SMN1 gene and/or associatedwith loss or defect of SMN1 gene function, particularly for thetreatment or prevention of spinal muscular atrophy (SMA).

A particular embodiment of the present invention relates to the use ofcompounds of formula (I) or their pharmaceutically acceptable salts asdefined above for the preparation of medicaments for the treatment orprevention of diseases caused by an inactivating mutation or deletion inthe SMN1 gene and/or associated with loss or defect of SMN1 genefunction, particularly for the treatment or prevention of spinalmuscular atrophy (SMA). Such medicaments comprise compounds of formula(I) or their pharmaceutically acceptable salts as defined above.

EXAMPLES

The invention will be more fully understood by reference to thefollowing examples. They should however not be construed as limiting thescope of the invention.

Abbreviations Used

ACN: Acetonitrile; CH₂Cl₂: dichloromethane; DIPEA: diisopropylethylamine; DMA: dimethyl acetamide; TEA: triethylamine; RT: roomtemperature; B₂(pin)₂: bis(pinacolato)diboron; Pd(dppf)C₁₋₂:(1,1′-Bis(diphenylphosphino)ferrocene)palladium(II) dichloride; PPTS:Pyridinium p-toluenesulfonate.

Intermediate 17-fluoro-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-onea) 2-chloro-7-fluoro-pyrido[1,2-a]pyrimidin-4-one

A mixture of 2-amino-5-fluoropyridine (11.20 g, 0.10 mol) and dimethylmalonate (57.0 mL, 0.50 mol) was heated at 230° C. for 1.5 h. Aftercooling to room temperature, the precipitate was filtered and washedwith ACN (3×) to give 7-fluoro-2-hydroxy-4H-pyrido[1,2-a]pyrimidin-4-oneas a dark solid (14 g), which was used directly in the next step. MS m/z181.3 [M+H]⁺.

A dark mixture of crude7-fluoro-2-hydroxy-4H-pyrido[1,2-a]pyrimidin-4-one (14 g, 77 mmol) inPOCl₃ (50 mL) and DIPEA (13.3 mL, 77 mmol) was heated at 110° C. for 15hours. The solvent was removed and the dark residue was treated withice-water, washed with water (3×) and dried to give a brown solid. Thecrude brown solid was chromatographed (5% MeOH in CH₂Cl₂) to give2-chloro-7-fluoro-4H-pyrido[1,2-a]pyrimidin-4-one as a yellow solid(9.84 g, 50%, 2 steps), MS m/z 199.2 [M+H]⁺.

b)2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)imidazo[1,2-b]pyridazine

A mixture of 6-chloro-2-methylimidazo[1,2-b]pyridazine (900 mg, 5.37mmol), 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (1.36g, 5.37 mmol, 1.0 eq.), KOAc (1.05 g, 10.7 mmol) and Pd(dppf)Cl₂.CH₂Cl₂(393 mg, 0.54 mmol) in dioxane (50 mL) was degassed and heated under N₂at 95° C. After 15 hours, the mixture was diluted with EtOAc, filteredthrough celite and concentrated under vacuum to give2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)imidazo[1,2-b]pyridazinewhich was used directly in the next step.

c)7-fluoro-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one

To a solution of 2-chloro-7-fluoro-4H-pyrido[1,2-a]pyrimidin-4-one (750mg, 3.78 mmol) in ACN (36 mL) was added2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)imidazo[1,2-b]pyridazine(1.17 g, 4.53 mmol, Eq: 1.2), Pd(Ph₃P)₄ (218 mg, 0.189 mmol, 0.05 eq.)and an aqueous solution of K₂CO₃ (3.78 mL, 7.55 mmol, 2.0 eq.). Themixture was degassed and heated under argon at 105° C. overnight. Thereaction was cooled to RT, and filtered. The precipitate was washed withEt₂O and then water, dried in vacuo to give 250 mg (22%) of7-fluoro-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-oneas a light brown solid. MS m/z 296.1 [M+H]⁺.

Intermediate 22-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-fluoro-pyrido[1,2-a]pyrimidin-4-onea)2,8-dimethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)imidazo[1,2-b]pyridazine

In a sealed flask, 3,6-dichloro-4-methylpyridazine (27 g, 161 mmol) wassuspended in aqueous ammonia (25%, 300 mL). The reaction mixture washeated at 110° C. for 48 hours (turned into solution after 1 hour).After cooling to room temperature, the reaction was poured into CH₂Cl₂,and the organic phase was separated, dried over Na₂SO₄, and concentratedunder vacuum, to give 22.4 g of 6-chloro-4-methyl-pyridazin-3-amine and6-chloro-5-methyl-pyridazin-3-amine as a mixture of regioisomers whichwere used directly in the next step.

The mixture of regioisomers 6-chloro-4-methyl-pyridazin-3-amine and6-chloro-5-methyl-pyridazin-3-amine (22.4 g) was suspended in 2-propanol(300 mL). 1-bromo-2,2-dimethoxypropane (36.0 g, 26.6 mL, 193 mmol, 1.2eq.) and PPTS (2.96 g, 11.6 mmol, 0.0725 eq.) were added, and theresulting solution was heated at 105° C. overnight. The solvent wasremoved in vacuo and the residue was taken up in CH₂Cl₂ and washed withNaHCO₃. The organic phases were dried over Na₂SO₄, concentrated in vacuoand the crude light brown solid was chromatographed (EtOAc/Heptane1/2-1/1) to give separately 6.1 g of6-chloro-2,8-dimethyl-imidazo[1,2-b]pyridazine MS m/z 182.1 [M+H]⁺ (21%)as a white solid and 5.9 g of6-chloro-2,7-dimethyl-imidazo[1,2-b]pyridazine MS m/z 182.1 [M+H]+(20%)as a white solid.

A mixture of 6-chloro-2,8-dimethylimidazo[1,2-b]pyridazine (0.9 g, 4.96mmol), 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (1.26g, 4.96 mmol, 1.0 eq.), KOAc (0.97 g, 9.91 mmol) and Pd(dppf)Cl₂.CH₂Cl₂(363 mg, 0.49 mmol) in dioxane (50 mL) was degassed and heated under N₂at 110° C. After 15 hours, the mixture was diluted with EtOAc, filteredthrough celite and concentrated under vacuum to give2,8-dimethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)imidazo[1,2-b]pyridazinewhich was used directly in the next step.

b)2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-fluoro-pyrido[1,2-a]pyrimidin-4-one

To a solution of 2-chloro-7-fluoro-4H-pyrido[1,2-a]pyrimidin-4-one (750mg, 3.78 mmol, described herein above) in ACN (36 mL) was added2,8-dimethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)imidazo[1,2-b]pyridazine(1.24 g, 4.53 mmol, 1.2 eq.), Pd(Ph₃P)₄ (218 mg, 0.189 mmol, 0.05 eq.)and an aqueous solution of K₂CO₃ (3.78 mL, 7.55 mmol, 2.0 eq.). Themixture was degassed and heated under argon at 100° C. for 6 hours. Thereaction was cooled to RT, and filtered. The precipitate was washed withEt₂O and then water, dried in vacuo to give 700 mg (60%) of2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-fluoro-pyrido[1,2-a]pyrimidin-4-oneas alight brown solid. MS m/z 310.1 [M+H]⁺.

Intermediate 37-fluoro-9-methyl-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-onea) 2-chloro-7-fluoro-9-methyl-pyrido[1,2-a]pyrimidin-4-one

A mixture of 5-fluoro-3-methylpyridin-2-amine (3.3 g, 26.2 mmol) anddimethyl malonate (15.0 mL, 0.13 mol, 5.0 eq.) was heated at 210° C. for1.5 hours. After cooling to room temperature, the precipitate wasfiltered and washed with ACN (3×) to give7-fluoro-2-hydroxy-9-methyl-pyrido[1,2-a]pyrimidin-4-one as a dark solid(2.3 g), which was used directly in the next step. MS m/z 195.1 [M+H]⁺.

A mixture of crude7-fluoro-2-hydroxy-9-methyl-pyrido[1,2-a]pyrimidin-4-one (2.3 g, 11.8mmol) in POCl₃ (7.7 mL, 82.9 mmol) and DIEA (2.07 mL, 11.8 mmol) washeated at 110° C. for 15 hours. The solvent was removed and the residuewas treated with ice-water, washed with water (3×) and dried to give abrown solid. The crude brown solid was chromatographed (5% MeOH inCH₂Cl₂) to give 2-chloro-7-fluoro-9-methyl-pyrido[1,2-a]pyrimidin-4-oneas a yellow solid (1.77 g, 70% over 2 steps), MS m/z 213.1 [M+H]⁺.

b)7-fluoro-9-methyl-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one

To a solution of2-chloro-7-fluoro-9-methyl-4H-pyrido[1,2-a]pyrimidin-4-one (2.2 g, 10.3mmol) in ACN (80 mL) was added2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)imidazo[1,2-b]pyridazine(3.22 g, 12.4 mmol, 1.2 eq., described herein above), Pd(Ph₃P)₄ (1.20 g,1.03 mmol, 0.1 eq.) and an aqueous solution of K₂CO₃ (10.3 mL, 20.7mmol, 2.0 eq.). The mixture was degassed and heated under argon at 100°C. for 6 hours. The reaction was cooled to RT, and filtered. Theprecipitate was washed with Et₂O and then water, dried in vacuo to give1.80 g (56%) of7-fluoro-9-methyl-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-oneas a light brown solid. MS m/z 310.1 [M+H]⁺.

Intermediate 42-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-fluoro-9-methyl-pyrido[1,2-a]pyrimidin-4-one

To a solution of2-chloro-7-fluoro-9-methyl-4H-pyrido[1,2-a]pyrimidin-4-one (0.98 g,mmol, described herein above) in ACN (50 mL) was added2,8-dimethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)imidazo[1,2-b]pyridazine(1.51 g, 5.53 mmol, 1.2 eq., described herein above), Pd(Ph₃P)₄ (0.32 g,0.277 mmol, 0.06 eq.) and an aqueous solution of K₂CO₃ (4.61 mL, 9.22mmol, 2.0 eq.). The mixture was degassed and heated under argon at 100°C. for 6 hours. The reaction was cooled to RT, and filtered. Theprecipitate was washed with Et₂O and water, then dried in vacuo to give0.89 g (60%) of2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-fluoro-9-methyl-pyrido[1,2-a]pyrimidin-4-oneas a light brown solid. MS m/z 324.4 [M+H]⁺.

Example 12-(2-methylimidazo[1,2-b]pyridazin-6-yl)-7-(4-methylpiperazin-1-yl)pyrido[1,2-a]pyrimidin-4-one

In a sealed tube,7-fluoro-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one(Intermediate 1; 35 mg, 0.119 mmol) and 1-methylpiperazine (47.5 mg,0.474 mmol, 4 eq.) were stirred in DMSO (1 mL) at 120° C. overnight.LC-MS showed total convertion. The solvent was removed under highvacuum. The crude product was purified by column chromatography (SiO₂,CH₂Cl₂/MeOH=95/5 to 9/1) to afford the title product (25 mg, 56%) as alight yellow solid. MS m/z 376.3 [M+H⁺].

Example 27-[(8aR)-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazin-2-yl]-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one

In a sealed tube,7-fluoro-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one(Intermediate 1; 125 mg, 0.426 mmol) and(R)-octahydropyrrolo-[1,2-a]pyrazine (160 mg, 1.27 mmol, 3 eq.) werestirred in DMSO (5 mL) at 125° C. overnight. The solvent was removedunder high vacuum. The residue was taken up in CH₂Cl₂ and washed with anaqueous saturated solution of NaHCO₃. The organic layer was separatedand dried over Na₂SO₄ and concentrated in vacuo. The crude was purifiedby column chromatography (SiO₂, CH₂Cl₂/MeOH=98/2 to 95/5) to afford thetitle product (65 mg, 38%) as a light yellow solid. MS m/z 402.5 [M+H⁺].

Example 37-[(8aS)-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazin-2-yl]-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one

In a sealed tube,2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-fluoro-pyrido[1,2-a]pyrimidin-4-one(Intermediate 2; 200 mg, 0.647 mmol) and(S)-octahydropyrrolo-[1,2-a]pyrazine (286 mg, 2.26 mmol, 3.5 eq.) werestirred in DMSO (5 mL) at 125° C. overnight. The solvent was removedunder high vacuum. The residue was taken up in CH₂Cl₂ and washed with anaqueous saturated solution of NaHCO₃. The organic layer was separatedand dried over Na₂SO₄ and concentrated in vacuo. The crude was purifiedby column chromatography (SiO₂, CH₂Cl₂/MeOH=98/2 to 95/5) to afford thetitle product (115 mg, 43%) as a light yellow solid. MS m/z 416.3[M+H⁺].

Example 47-[(8aR)-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazin-2-yl]-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one

In a sealed tube,2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-fluoro-pyrido[1,2-a]pyrimidin-4-one(Intermediate 2; 200 mg, 0.647 mmol), DIPEA (0.113 mL, 0.67 mmol, 1 eq.)and (R)-octahydropyrrolo-[1,2-a]pyrazine (245 mg, 1.95 mmol, 3.0 eq.)were stirred in DMSO (2.5 mL) at 125° C. overnight. The solvent wasremoved under high vacuum. The residue was taken up in CH₂Cl₂ and washedwith an aqueous saturated solution of NaHCO₃. The organic layer wasseparated and dried over Na₂SO₄ and concentrated in vacuo. The crude waspurified by column chromatography (SiO₂, CH₂Cl₂/MeOH=98/2 to 95/5) toafford the title product (132 mg, 49%) as a light yellow solid. MS m/z416.3 [M+H⁺].

Example 57-[(8aS)-8a-methyl-1,3,4,6,7,8-hexahydropyrrolo[1,2-a]pyrazin-2-yl]-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one

In a sealed tube,2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-fluoro-pyrido[1,2-a]pyrimidin-4-one(Intermediate 2; 90 mg, 0.291 mmol), DIPEA (0.05 mL, 0.29 mmol, 1 eq.)and (S)-8a-methyloctahydropyrrolo[1,2-a]pyrazine (81 mg, 0.58 mmol, 2.0eq.) were stirred in DMSO (2.5 mL) at 125° C. overnight. The solvent wasremoved under high vacuum. The residue was taken up in CH₂Cl₂ and washedwith an aqueous saturated solution of NaHCO₃. The organic layer wasseparated and dried over Na₂SO₄ and concentrated in vacuo. The crude waspurified by column chromatography (SiO₂, CH₂Cl₂/MeOH=95/5 to 90/10) toafford the title product (55 mg, 44%) as a light yellow solid. MS m/z430.3 [M+H⁺].

Example 67-[(8aR)-8a-methyl-1,3,4,6,7,8-hexahydropyrrolo[1,2-a]pyrazin-2-yl]-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one

In a sealed tube,2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-fluoro-pyrido[1,2-a]pyrimidin-4-one(Intermediate 2; 90 mg, 0.291 mmol), DIPEA (0.05 mL, 0.29 mmol, 1 eq.)and (R)-8a-methyloctahydropyrrolo[1,2-a]pyrazine (81 mg, 0.58 mmol, 2.0eq.) were stirred in DMSO (2.5 mL) at 125° C. overnight. The solvent wasremoved under high vacuum. The residue was taken up in CH₂Cl₂ and washedwith an aqueous saturated solution of NaHCO₃. The organic layer wasseparated and dried over Na₂SO₄ and concentrated in vacuo. The crude waspurified by column chromatography (SiO₂, CH₂Cl₂/MeOH=95/5 to 90/10) toafford the title product (50 mg, 40%) as a light yellow solid. MS m/z430.4 [M+H⁺].

Example 72-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-[(3S,5R)-3,5-dimethylpiperazin-1-yl]pyrido[1,2-a]pyrimidin-4-one

In a sealed tube,2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-fluoro-pyrido[1,2-a]pyrimidin-4-one(Intermediate 2; 50 mg, 0.162 mmol), and cis-2,6-dimethylpiperazine (74mg, 0.647 mmol, 4.0 eq.) were stirred in DMSO (1.5 mL) at 110° C.overnight. The solvent was removed under high vacuum. The residue wastaken up in CH₂Cl₂ and washed with an aqueous saturated solution ofNaHCO₃. The organic layer was separated and dried over Na₂SO₄ andconcentrated in vacuo. The crude was purified by column chromatography(SiO₂, CH₂Cl₂/MeOH=95/5 to 90/10) to afford the title product (32 mg,49%) as a light yellow solid. MS m/z 404.4 [M+H⁺].

Example 82-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-[(3S)-3-methylpiperazin-1-yl]pyrido[1,2-a]pyrimidin-4-one

In a sealed tube,2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-fluoro-pyrido[1,2-a]pyrimidin-4-one(Intermediate 2; 33 mg, 0.107 mmol), and (S)-2-methylpiperazine (43 mg,0.427 mmol, 4.0 eq.) were stirred in DMSO (2 mL) at 120° C. overnight.The solvent was removed under high vacuum. The residue was taken up inCH₂Cl₂ and washed with an aqueous saturated solution of NaHCO₃. Theorganic layer was separated and dried over Na₂SO₄ and concentrated invacuo. The crude was purified by column chromatography (SiO₂,CH₂Cl₂/MeOH=95/5 to 90/10) to afford the title product (18 mg, 43%) as alight yellow solid. MS m/z 390.3 [M+H⁺].

Example 92-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-[(3R)-3-methylpiperazin-1-yl]pyrido[1,2-a]pyrimidin-4-one

In a sealed tube,2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-fluoro-pyrido[1,2-a]pyrimidin-4-one(Intermediate 2; 85 mg, 0.275 mmol), and (R)-2-methylpiperazine (110 mg,1.10 mmol, 4.0 eq.) were stirred in DMSO (5 mL) at 120° C. overnight.The solvent was removed under high vacuum. The residue was taken up inCH₂Cl₂ and washed with an aqueous saturated solution of NaHCO₃. Theorganic layer was separated and dried over Na₂SO₄ and concentrated invacuo. The crude was purified by column chromatography (SiO₂,CH₂Cl₂/MeOH=95/5 to 90/10) to afford the title product (35 mg, 33%) as alight yellow solid. MS m/z 390.3 [M+H⁺].

Example 107-(1,4-diazepan-1-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one

In a sealed tube,2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-fluoro-pyrido[1,2-a]pyrimidin-4-one(Intermediate 2; 33 mg, 0.107 mmol), and 1,4-diazepane (32 mg, 0.320mmol, 3.0 eq.) were stirred in DMSO (2 mL) at 120° C. overnight. Thesolvent was removed under high vacuum. The residue was taken up inCH₂Cl₂ and washed with an aqueous saturated solution of NaHCO₃. Theorganic layer was separated and dried over Na₂SO₄ and concentrated invacuo. The crude was purified by column chromatography (Si₂,CH₂Cl₂/MeOH=95/5 to 90/10) to afford te title product (20 mg, 48%) as alight yellow solid. MS m/z 390.3 [M+H⁺].

Example 112-(2-methylimidazo[1,2-b]pyridazin-6-yl)-7-[(3S)-3-methylpiperazin-1-yl]pyrido[1,2-a]pyrimidin-4-one

In a sealed tube,7-fluoro-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one(Intermediate 1; 50 mg, 0.169 mmol), and (S)-2-methylpiperazine (68 mg,0.677 mmol, 4.0 eq.) were stirred in DMSO (2 mL) at 110° C. overnight.The solvent was removed under high vacuum. The residue was taken up inCH₂Cl₂ and washed with an aqueous saturated solution of NaHCO₃. Theorganic layer was separated and dried over Na₂SO₄ and concentrated invacuo. The crude was purified by column chromatography (SiO₂,CH₂Cl₂/MeOH=95/5 to 90/10) to afford the title product (40 mg, 63%) as alight yellow solid. MS m/z 376.2 [M+H⁺].

Example 122-(2-methylimidazo[1,2-b]pyridazin-6-yl)-7-[(3R)-3-methylpiperazin-1-yl]pyrido[1,2-a]pyrimidin-4-one

In a sealed tube,7-fluoro-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one(Intermediate 1; 50 mg, 0.169 mmol), and (R)-2-methylpiperazine (68 mg,0.677 mmol, 4.0 eq.) were stirred in DMSO (2 mL) at 110° C. overnight.The solvent was removed under high vacuum. The residue was taken up inCH₂Cl₂ and washed with an aqueous saturated solution of NaHCO₃. Theorganic layer was separated and dried over Na₂SO₄ and concentrated invacuo. The crude was purified by column chromatography (SiO₂,CH₂Cl₂/MeOH=95/5 to 90/10) to afford the title product (48 mg, 75%) as alight yellow solid. MS m/z 376.3 [M+H⁺].

Example 137-(1,4-diazepan-1-yl)-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one

In a sealed tube,7-fluoro-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one(Intermediate 1; 50 mg, 0.169 mmol), and 1,4-diazepane (68 mg, 0.677mmol, 4.0 eq.) were stirred in DMSO (2 mL) at 110° C. overnight. Thesolvent was removed under high vacuum. The residue was taken up inCH₂Cl₂ and washed with an aqueous saturated solution of NaHCO₃. Theorganic layer was separated and dried over Na₂SO₄ and concentrated invacuo. The crude was purified by column chromatography (Si₂,CH₂Cl₂/MeOH=95/5 to 90/10) to afford the title product (41 mg, 65%) as alight yellow solid. MS m/z 376.2 [M+H⁺].

Example 147-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one

In a sealed tube,7-fluoro-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one(Intermediate 1; 50 mg, 0.169 mmol), and cis-2,6-dimethylpiperazine (77mg, 0.677 mmol, 4.0 eq.) were stirred in DMSO (2 mL) at 110° C.overnight. The solvent was removed under high vacuum. The residue wastaken up in CH₂Cl₂ and washed with an aqueous saturated solution ofNaHCO₃. The organic layer was separated and dried over Na₂SO₄ andconcentrated in vacuo. The crude was purified by column chromatography(SiO₂, CH₂Cl₂/MeOH=95/5 to 90/10) to afford the title product (41 mg,62%) as a light yellow solid. MS m/z 390.3 [M+H⁺].

Example 157-[(8aS)-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazin-2-yl]-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one

In a sealed tube,7-fluoro-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one(Intermediate 1; 50 mg, 0.169 mmol), and(S)-octahydropyrrolo[1,2-a]pyrazine (85 mg, 0.677 mmol, 4.0 eq.) werestirred in DMSO (2 mL) at 125° C. overnight. The solvent was removedunder high vacuum. The residue was taken up in CH₂Cl₂ and washed with anaqueous saturated solution of NaHCO₃. The organic layer was separatedand dried over Na₂SO₄ and concentrated in vacuo. The crude was purifiedby column chromatography (SiO₂, CH₂Cl₂/MeOH=95/5 to 90/10) to afford thetitle product (36 mg, 53%) as a light yellow solid. MS m/z 402.3 [M+H⁺].

Example 167-[(8aS)-8a-methyl-1,3,4,6,7,8-hexahydropyrrolo[1,2-a]pyrazin-2-yl]-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one

In a sealed tube,7-fluoro-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one(Intermediate 1; 50 mg, 0.169 mmol) and(S)-8a-methyloctahydropyrrolo[1,2-a]pyrazine (95 mg, 0.677 mmol, 4.0eq.) were stirred in DMSO (2 mL) at 125° C. overnight. The solvent wasremoved under high vacuum. The residue was taken up in CH₂Cl₂ and washedwith an aqueous saturated solution of NaHCO₃. The organic layer wasseparated and dried over Na₂SO₄ and concentrated in vacuo. The crude waspurified by column chromatography (SiO₂, CH₂Cl₂/MeOH=95/5 to 90/10) toafford the title product (45 mg, 64%) as a light yellow solid. MS m/z416.3 [M+H⁺].

Example 177-[(8aR)-8a-methyl-1,3,4,6,7,8-hexahydropyrrolo[1,2-a]pyrazin-2-yl]-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one

In a sealed tube,7-fluoro-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one(Intermediate 1; 100 mg, 0.339 mmol) and(R)-8a-methyloctahydropyrrolo[1,2-a]pyrazine (190 mg, 1.35 mmol, 4.0eq.) were stirred in DMSO (4 mL) at 125° C. overnight. The solvent wasremoved under high vacuum. The residue was taken up in CH₂Cl₂ and washedwith an aqueous saturated solution of NaHCO₃. The organic layer wasseparated and dried over Na₂SO₄ and concentrated in vacuo. The crude waspurified by column chromatography (SiO₂, CH₂Cl₂/MeOH=95/5 to 90/10) toafford the title product (45 mg, 64%) as a light yellow solid. MS m/z416.3 [M+H⁺].

Example 182-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-[(3R)-3-pyrrolidin-1-ylpyrrolidin-1-yl]pyrido[1,2-a]pyrimidin-4-one

In a microwave reactor,2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-fluoro-pyrido[1,2-a]pyrimidin-4-one(Intermediate 2; 45 mg, 0.145 mmol), (R)-1,3′-bipyrrolidinedihydrochloride (62 mg, 0.291 mmol, 2.0 eq.) and DIPEA (0.20 mL, 1.16mmol, 8 eq.) were stirred in NMP (3 mL) at 220° C. for 1 hour. Thesolvent was removed under high vacuum. The residue was taken up inCH₂Cl₂ and washed with an aqueous saturated solution of NaHCO₃. Theorganic layer was separated and dried over Na₂SO₄ and concentrated invacuo. The crude was purified by column chromatography (SiO₂,CH₂Cl₂/MeOH=98/2 to 90/10) to afford the title product (25 mg, 40%) as alight yellow solid. MS m/z 430.3 [M+H⁺].

Example 197-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one

In a sealed tube,7-fluoro-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one(Intermediate 1; 50 mg, 0.169 mmol), DIPEA (0.24 mL, 1.35 mmol, 8 eq.)and 4,7-diazaspiro[2.5]octane dihydrochloride (62.7 mg, 0.339 mmol, 2.0eq.) were stirred in DMSO (2 mL) at 125° C. for 2 days. The solvent wasremoved under high vacuum. The residue was taken up in CH₂Cl₂ and washedwith an aqueous saturated solution of NaHCO₃. The organic layer wasseparated and dried over Na₂SO₄ and concentrated in vacuo. The crude waspurified by column chromatography (SiO₂, CH₂Cl₂/MeOH=95/5 to 90/10) toafford the title product (22 mg, 33%) as a light yellow solid. MS m/z388.3 [M+H⁺].

Example 207-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one

In a sealed tube,2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-fluoro-pyrido[1,2-a]pyrimidin-4-one(Intermediate 2; 50 mg, 0.162 mmol), DIPEA (0.22 mL, 1.29 mmol, 4 eq.)and 4,7-diazaspiro[2.5]octane dihydrochloride (32 mg, 0.320 mmol, 3.0eq.) were stirred in DMSO (2 mL) at 130° C. for 48 hours. The solventwas removed under high vacuum. The residue was taken up in CH₂Cl₂ andwashed with an aqueous saturated solution of NaHCO₃. The organic layerwas separated and dried over Na₂SO₄ and concentrated in vacuo. The crudewas purified by column chromatography (SiO₂, CH₂Cl₂/MeOH=98/2 to 95/5)to afford the title product (12 mg, 18%) as a light yellow solid. MS m/z402.3 [M+H⁺].

Example 212-(2-methylimidazo[1,2-b]pyridazin-6-yl)-7-[(3R)-3-pyrrolidin-1-ylpyrrolidin-1-yl]pyrido[1,2-a]pyrimidin-4-one

In a sealed tube,7-fluoro-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one(Intermediate 1; 40 mg, 0.135 mmol), DIPEA (0.19 mL, 1.08 mmol, 8 eq.)and (R)-1,3′-bipyrrolidine dihydrochloride (58 mg, 0.271 mmol, 2.0 eq.)were stirred in DMSO (4 mL) and heated at 220° C. for 40 minutes in amicrowave. The solvent was removed under high vacuum. The residue wastaken up in CH₂Cl₂ and washed with an aqueous saturated solution ofNaHCO₃. The organic layer was separated and dried over Na₂SO₄ andconcentrated in vacuo. The crude was purified by column chromatography(SiO₂, CH₂Cl₂/MeOH=98/2 to 90/10) to afford the title product (30 mg,53%) as a light yellow solid. MS m/z 416.3 [M+H⁺].

Example 222-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-(3,3-dimethylpiperazin-1-yl)pyrido[1,2-a]pyrimidin-4-one

In a sealed tube,2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-fluoro-pyrido[1,2-a]pyrimidin-4-one(Intermediate 2; 40 mg, 0.129 mmol) and 2,2-dimethylpiperazine (59 mg,0.517 mmol, 4.0 eq.) were stirred in DMSO (1.6 mL) at 130° C. overnight.The solvent was removed under high vacuum. The residue was taken up inCH₂Cl₂ and washed with an aqueous saturated solution of NaHCO₃. Theorganic layer was separated and dried over Na₂SO₄ and concentrated invacuo. The crude was purified by column chromatography (SiO₂,CH₂Cl₂/MeOH=95/5 to 9/1) to afford the title product (29 mg, 55%) as alight yellow solid. MS m/z 404.3 [M+H⁺].

Example 237-(3,3-dimethylpiperazin-1-yl)-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one

In a sealed tube,7-fluoro-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one(Intermediate 1; 40 mg, 0.135 mmol) and 2,2-dimethylpiperazine (62 mg,0.542 mmol, 4.0 eq.) were stirred in DMSO (2 mL) at 130° C. overnight.The solvent was removed under high vacuum. The residue was taken up inCH₂Cl₂ and washed with an aqueous saturated solution of NaHCO₃. Theorganic layer was separated and dried over Na₂SO₄ and concentrated invacuo. The crude was purified by column chromatography (SiO₂,CH₂Cl₂/MeOH=95/5 to 90/10) to afford the title product (26 mg, 49%) as alight yellow solid. MS m/z 390.3 [M+H⁺].

Example 242-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-9-methyl-7-[(3S)-3-methylpiperazin-1-yl]pyrido[1,2-a]pyrimidin-4-one

In a sealed tube,2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-fluoro-9-methyl-pyrido[1,2-a]pyrimidin-4-one(Intermediate 4; 50 mg, 0.155 mmol) and (S)-2-methylpiperazine (62 mg,0.619 mmol, 4.0 eq.) were stirred in DMSO (2 mL) at 125° C. overnight.The solvent was removed under high vacuum. The residue was taken up inCH₂Cl₂ and washed with an aqueous saturated solution of NaHCO₃. Theorganic layer was separated and dried over Na₂SO₄ and concentrated invacuo. The crude was purified by column chromatography (SiO₂,CH₂Cl₂/MeOH=95/5 to 90/10) to afford the title product (45 mg, 72%) as alight yellow solid. MS m/z 404.3 [M+H⁺].

Example 252-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-9-methyl-7-[(3R)-3-methylpiperazin-1-yl]pyrido[1,2-a]pyrimidin-4-one

In a sealed tube,2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-fluoro-9-methyl-pyrido[1,2-a]pyrimidin-4-one(Intermediate 4; 50 mg, 0.155 mmol) and (R)-2-methylpiperazine (62 mg,0.619 mmol, 4.0 eq.) were stirred in DMSO (2 mL) at 125° C. overnight.The solvent was removed under high vacuum. The residue was taken up inCH₂Cl₂ and washed with an aqueous saturated solution of NaHCO₃. Theorganic layer was separated and dried over Na₂SO₄ and concentrated invacuo. The crude was purified by column chromatography (SiO₂,CH₂Cl₂/MeOH=95/5 to 90/10) to afford the title product (40 mg, 70%) as alight yellow solid. MS m/z 404.3 [M+H⁺].

Example 262-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-9-methyl-pyrido[1,2-a]pyrimidin-4-one

In a sealed tube,2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-fluoro-9-methyl-pyrido[1,2-a]pyrimidin-4-one(Intermediate 4; 50 mg, 0.155 mmol) and cis-2,6-dimethylpiperazine (70mg, 0.619 mmol, 4.0 eq.) were stirred in DMSO (2 mL) at 125° C.overnight. The solvent was removed under high vacuum. The residue wastaken up in CH₂Cl₂ and washed with an aqueous saturated solution ofNaHCO₃. The organic layer was separated and dried over Na₂S04 andconcentrated in vacuo. The crude was purified by column chromatography(SiO₂, CH₂Cl₂/MeOH=95/5 to 90/10) to afford the title product (26 mg,40%) as a light yellow solid. MS m/z 418.3 [M+H⁺].

Example 272-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-(3,3-dimethylpiperazin-1-yl)-9-methyl-pyrido[1,2-a]pyrimidin-4-one

In a sealed tube,2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-fluoro-9-methyl-pyrido[1,2-a]pyrimidin-4-one(Intermediate 4; 50 mg, 0.155 mmol) and 2,2-dimethylpiperazine (35 mg,0.309 mmol, 2.0 eq.) were stirred in DMSO (2 mL) at 125° C. overnight.The solvent was removed under high vacuum. The residue was taken up inCH₂Cl₂ and washed with an aqueous saturated solution of NaHCO₃. Theorganic layer was separated and dried over Na₂SO₄ and concentrated invacuo. The crude was purified by column chromatography (SiO₂,CH₂Cl₂/MeOH=95/5 to 90/10) to afford the title product (36 mg, 56%) as alight yellow solid. MS m/z 418.3 [M+H⁺].

Example 287-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-9-methyl-pyrido[1,2-a]pyrimidin-4-one

In a sealed tube,2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-fluoro-9-methyl-pyrido[1,2-a]pyrimidin-4-one(Intermediate 4; 50 mg, 0.155 mmol), DIPEA (0.21 mL, 1.24 mmol, 8 eq.)and 4,7-diazaspiro[2.5]octane dihydrochloride (57 mg, 0.309 mmol, 2.0eq.) were stirred in DMSO (2 mL) at 125° C. for 2 days. The solvent wasremoved under high vacuum. The residue was taken up in CH₂Cl₂ and washedwith an aqueous saturated solution of NaHCO₃. The organic layer wasseparated and dried over Na₂SO₄ and concentrated in vacuo. The crude waspurified by column chromatography (SiO₂, CH₂Cl₂/MeOH=95/5 to 90/10) toafford the title product (17 mg, 26%) as a light yellow solid. MS m/z416.3 [M+H⁺].

Example 292-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-[(3S,5S)-3,5-dimethylpiperazin-1-yl]pyrido[1,2-a]pyrimidin-4-one

In a sealed tube,2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-fluoro-pyrido[1,2-a]pyrimidin-4-one(Intermediate 2; 50 mg, 0.162 mmol), TEA (0.18 mL, 1.29 mmol, 8 eq.) and(2S,6S)-2,6-dimethylpiperazine dihydrochloride (90 mg, 0.485 mmol, 3.0eq.) were stirred in DMSO (2 mL) at 140° C. overnight. The solvent wasremoved under high vacuum. The residue was taken up in CH₂Cl₂ and washedwith an aqueous saturated solution of NaHCO₃. The organic layer wasseparated and dried over Na₂SO₄ and concentrated in vacuo. The crude waspurified by column chromatography (SiO₂, CH₂Cl₂/MeOH=95/5 to 9/1) toafford the title product (20 mg, 30%) as a light yellow solid. MS m/z404.3 [M+H⁺].

Example 302-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-[(3S)-3-pyrrolidin-1-ylpyrrolidin-1-yl]pyrido[1,2-a]pyrimidin-4-one

In a sealed tube,2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-fluoro-pyrido[1,2-a]pyrimidin-4-one(Intermediate 2; 50 mg, 0.162 mmol), DIPEA (0.22 mL, 1.29 mmol, 8 eq.)and (S)-1,3′-bipyrrolidine dihydrochloride (103 mg, 0.485 mmol, 3.0 eq.)were stirred in NMP (2 mL) at 140° C. overnight. The solvent was removedunder high vacuum. The residue was taken up in CH₂Cl₂ and washed with anaqueous saturated solution of NaHCO₃. The organic layer was separatedand dried over Na₂SO₄ and concentrated in vacuo. The crude was purifiedby column chromatography (SiO₂, CH₂Cl₂/MeOH=95/5 to 9/1) to afford thetitle product (22 mg, 32%) as a light yellow solid. MS m/z 430.3 [M+H⁺].

Example 312-(2-methylimidazo[1,2-b]pyridazin-6-yl)-7-[(3S)-3-pyrrolidin-1-ylpyrrolidin-1-yl]pyrido[1,2-a]pyrimidin-4-one

In a sealed tube,7-fluoro-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one(Intermediate 1; 75 mg, 0.254 mmol), TEA (0.28 mL, 2.03 mmol, 8 eq.) and(S)-1,3′-bipyrrolidine dihydrochloride (162 mg, 0.762 mmol, 3.0 eq.)were stirred in NMP (4 mL) and heated at 220° C. for 1 hour in amicrowave. The solvent was removed under high vacuum. The residue wastaken up in CH₂Cl₂ and washed with an aqueous saturated solution ofNaHCO₃. The organic layer was separated and dried over Na₂SO₄ andconcentrated in vacuo. The crude was purified by column chromatography(SiO₂, CH₂Cl₂/MeOH=95/5 to 90/10) to afford the title product (12 mg,11%) as a light yellow solid. MS m/z 416.2 [M+H⁺].

Example 327-[(3S,5S)-3,5-dimethylpiperazin-1-yl]-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one

In a sealed tube,7-fluoro-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one(Intermediate 1; 75 mg, 0.254 mmol), TEA (0.28 mL, 2.03 mmol, 8 eq.) and(2S,6S)-2,6-dimethylpiperazine dihydrochloride (143 mg, 0.762 mmol, 3.0eq.) were stirred in DMSO (3 mL) and heated at 140° C. overnight. Thesolvent was removed under high vacuum. The residue was taken up inCH₂Cl₂ and washed with an aqueous saturated solution of NaHCO₃. Theorganic layer was separated and dried over Na₂SO₄ and concentrated invacuo. The crude was purified by column chromatography (SiO₂,CH₂Cl₂/MeOH=95/5 to 90/10) to afford the title product (10 mg, 10%) as alight yellow solid. MS m/z 390.3 [M+H⁺].

Example 339-methyl-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)-7-[(3S)-3-methylpiperazin-1-yl]pyrido[1,2-a]pyrimidin-4-one

In a sealed tube,7-fluoro-9-methyl-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one(Intermediate 3; 250 mg, 0.808 mmol), and (S)-2-methylpiperazine (405mg, 4.04 mmol, 5.0 eq.) were stirred in DMSO (6 mL) and heated at 130°C. overnight. The solvent was removed under high vacuum. The residue wastaken up in CH₂Cl₂ and washed with an aqueous saturated solution ofNaHCO₃. The organic layer was separated and dried over Na₂SO₄ andconcentrated in vacuo. The crude was purified by column chromatography(SiO₂, CH₂Cl₂/MeOH=95/5 to 85/15) to afford the title product (135 mg,43%) as a light yellow solid. MS m/z 390.3 [M+H⁺].

Example 349-methyl-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)-7-[(3R)-3-methylpiperazin-1-yl]pyrido[1,2-a]pyrimidin-4-one

In a sealed tube,7-fluoro-9-methyl-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one(Intermediate 3; 250 mg, 0.808 mmol), and (R)-2-methylpiperazine (405mg, 4.04 mmol, 5.0 eq.) were stirred in DMSO (6 mL) and heated at 130°C. overnight. The solvent was removed under high vacuum. The residue wastaken up in CH₂Cl₂ and washed with an aqueous saturated solution ofNaHCO₃. The organic layer was separated and dried over Na₂SO₄ andconcentrated in vacuo. The crude was purified by column chromatography(SiO₂, CH₂Cl₂/MeOH=95/5 to 85/15) to afford the title product (100 mg,32%) as a light yellow solid. MS m/z 390.3 [M+H⁺].

Example 357-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-9-methyl-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one

In a sealed tube,7-fluoro-9-methyl-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one(Intermediate 3; 250 mg, 0.808 mmol), and (2S,6R)-2,6-dimethylpiperazine(461 mg, 4.04 mmol, 5.0 eq.) were stirred in DMSO (6 mL) and heated at130° C. overnight. The solvent was removed under high vacuum. Theresidue was taken up in CH₂Cl₂ and washed with an aqueous saturatedsolution of NaHCO₃. The organic layer was separated and dried overNa₂SO₄ and concentrated in vacuo. The crude was purified by columnchromatography (SiO₂, CH₂Cl₂/MeOH=95/5 to 85/15) to afford the titleproduct (101 mg, 31%) as a light yellow solid. MS m/z 404.3 [M+H⁺].

Example 367-(3,3-dimethylpiperazin-1-yl)-9-methyl-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one

In a sealed tube,7-fluoro-9-methyl-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one(Intermediate 3; 250 mg, 0.808 mmol), and 2,2-dimethylpiperazine (461mg, 4.04 mmol, 5.0 eq.) were stirred in DMSO (6 mL) and heated at 130°C. overnight. The solvent was removed under high vacuum. The residue wastaken up in CH₂Cl₂ and washed with an aqueous saturated solution ofNaHCO₃. The organic layer was separated and dried over Na₂SO₄ andconcentrated in vacuo. The crude was purified by column chromatography(SiO₂, CH₂Cl₂/MeOH=95/5 to 85/15) to afford the title product (120 mg,36%) as a light yellow solid. MS m/z 404.3 [M+H⁺].

Example 377-(4,7-diazaspiro[2.5]octan-7-yl)-9-methyl-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one

In a sealed tube,7-fluoro-9-methyl-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one(Intermediate 3; 125 mg, 0.404 mmol), K₂CO₃ (223 mg, 1.62 mmol, 4 eq.)and 4,7-diazaspiro[2.5]octane dihydrochloride (112 mg, 0.606 mmol, 1.5eq.) were stirred in DMA (2 mL) and heated at 130° C. overnight. Thesolvent was removed under high vacuum. The residue was taken up inCH₂Cl₂ and washed with an aqueous saturated solution of NaHCO₃. Theorganic layer was separated and dried over Na₂SO₄ and concentrated invacuo. The crude was purified by column chromatography (SiO₂,CH₂Cl₂/MeOH=95/5 to 90/10) to afford the title product (75 mg, 46%) as alight yellow solid. MS m/z 402.2 [M+H⁺].

Example 387-[(3S,5S)-3,5-dimethylpiperazin-1-yl]-9-methyl-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one

In a sealed tube,7-fluoro-9-methyl-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one(Intermediate 3; 125 mg, 0.404 mmol), K₂CO₃ (223 mg, 1.62 mmol, 4 eq.)and (2S,6S)-2,6-dimethylpiperazine dihydrochloride (113 mg, 0.606 mmol,1.5 eq.) were stirred in DMA (2 mL) and heated at 130° C. overnight. Thesolvent was removed under high vacuum. The residue was taken up inCH₂Cl₂ and washed with an aqueous saturated solution of NaHCO₃. Theorganic layer was separated and dried over Na₂SO₄ and concentrated invacuo. The crude was purified by column chromatography (SiO₂,CH₂Cl₂/MeOH=95/5 to 90/10) to afford the title product (50 mg, 31%) as alight yellow solid. MS m/z 404.3 [M+H⁺].

Example 397-[(3R)-3-ethylpiperazin-1-yl]-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one

In a sealed tube,7-fluoro-2-(2-methylimidazo[1,2-b]pyridazin-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one(Intermediate 1; 200 mg, 0.677 mmol), K₂CO₃ (374 mg, 2.71 mmol, 4 eq.)and (R)-2-ethylpiperazine dihydrochloride (238 mg, 0.606 mmol, 1.5 eq.)were stirred in DMA (3 mL) at 100° C. for 4 days. The solvent wasremoved under high vacuum. The crude was purified by columnchromatography (SiO₂, CH₂Cl₂/MeOH=95/5 to 8/2) to afford the titleproduct (168 mg, 64%) as a light yellow solid. MS m/z 390.2 [M+H⁺].

Biological Assays

To describe in more detail and assist in understanding the presentdescription, the following non-limiting biological examples are offeredto more fully illustrate the scope of the description and are not to beconstrued as specifically limiting the scope thereof. Such variations ofthe present description that may be now known or later developed, whichwould be within the purview of one skilled in the art to ascertain, areconsidered to fall within the scope of the present description and ashereinafter claimed. These examples illustrate the testing of certaincompounds described herein in vitro and/or in vivo and demonstrate theusefulness of the compounds for treating of SMA by enhancing theinclusion of exon 7 of SMN2 into mRNA transcribed from the SMN2 gene.Compounds of formula (I) enhance inclusion of exon 7 of SMN2 into mRNAtranscribed from the SMN2 gene and increase levels of SMN proteinproduced from the SMN2 gene, and thus can be used to treat SMA in ahuman subject in need thereof. These examples further illustrate thetesting of certain compounds described herein in vitro and/or in vivoand demonstrate the usefulness of the compounds for enhancing theinclusion of exon 7 of SMNI into mRNA transcribed from the SMN1 gene.Accordingly, compounds of formula (I) also enhance the inclusion of exon7 of SMN1 into mRNA transcribed from the SMN1 gene and increase levelsof SMN protein produced from the SMN1 gene.

Assay 1 SMN2 Minigene mRNA Splicing RT-qPCR Assay in Cultured Cells

The reverse transcription-quantitative PCR-based (RT-qPCR) assay is usedto quantify the level of the full length SMN2 minigene (referred toherein by the term “FL SMN2mini”) mRNA containing SMN2 exon 7 in aHEK293H cell line stably transfected with said minigene and treated witha test compound. Materials used and respective sources are listed belowin Table 1.

TABLE 1 Materials and their respective sources used in the SMN2 minigenemRNA splicing RT-qPCR assay in cultured cells. Material Source HEK293Hcells Life Technologies, Inc. (formerly Invitrogen) Catalog No.11631-017 Cells-To-Ct lysis Life Technologies, Inc. (formerly Appliedbuffer Biosystems) part No. 4399002 DMEM Life Technologies, Inc.(formerly Invitrogen) Catalog No. 11960-044 96-well flat-bottom BectonDickinson Catalog No. 353072 plates RT-PCR Enzyme Life Technologies,Inc. (formerly Applied Mix Biosystems) part No. 4388520 RT-PCR bufferLife Technologies, Inc. (formerly Applied Biosystems) part No. 4388519AgPath-ID One- Life Technologies, Inc. (formerly Applied Step RT-PCR kitBiosystems) part No. 4387391 Thermocycler Life Technologies, Inc.(formerly Applied Biosystems) 7900HT

The SMN2-A minigene construct was prepared as described in InternationalPatent Application WO2009/151546A1 page 145 paragraph [00400] to page147 paragraph [00412](incl. FIG. 1 and FIG. 3 therein).

HEK293H cells stably transfected with the SMN2-A minigene construct(10,000 cells/well) are seeded in 200 μL of cell culture medium (DMEMplus 10% FBS, with 200 μg/mL hygromycin) in 96-well flat-bottom platesand the plate is immediately swirled to ensure proper dispersal of cellsand the formation of an even monolayer of cells. Cells are allowed toattach for 6 hours. Test compounds are serially diluted 3.16-fold in100% DMSO to generate a 7-point concentration curve. A solution of testcompound (1 μL, 200× in DMSO) is added to each cell-containing well andthe plate is incubated for 24 hours in a cell culture incubator (37° C.,5% CO₂, 100% relative humidity). 2 replicates are prepared for each testcompound concentration. The cells are then lysed in the Cells-To-Ctlysis buffer and the lysate is stored at −80° C.

Full length SMN2-A minigene and GAPDH mRNA are quantified using theprimers and probes referenced in Table 2. Primer SMN Forward A (SEQ IDNO.1) hybridizes to a nucleotide sequence in exon 7 (nucleotide 22 tonucleotide 40), primer SMN Reverse A (SEQ ID NO.2) hybridizes to anucleotide sequence in the coding sequence of Firefly luciferase, SMNProbe A (SEQ ID NO.3) hybridizes to a nucleotide sequence in exon 7(nucleotide 50 to nucleotide 54) and exon 8 (nucleotide 1 to nucleotide21). The combination of these three oligonucleotides detects only SMN1or SMN2 minigenes (RT-qPCR) and will not detect endogenous SMN1 or SMN2genes.

TABLE 2 Primers/Probes Sequences Source SMN Forward SEQ ID NO. 1: PTC¹Primer A GAAGGAAGGTGCTCACATT SMN Reverse SEQ ID NO. 2: PTC¹ Primer ATCTTTATGTTTTTGGCGTCTTC SMN Forward SEQ ID NO. 3: 6FAM- PTC¹ Probe AAAGGAGAAATGCTGGCATAGAGCAGC- TAMRA hGAPDH Forward SEQ ID NO. 4: VIC- LTI²Probe CGCCTGGTCACCAGGGCTGCT- TAMRA hGAPDH Forward SEQ ID NO. 5:  LTI²Primer CAACGGATTTGGTCGTATTGG hGAPDH Reverse SEQ ID NO. 6: LTI² PrimerTGATGGCAACAATATCCACTTTACC ¹Primers and probes designed by PTCTherapeutics, Inc.; ²Commercially available from Life Technologies, Inc.(formerly Invitrogen).

The SMN forward and reverse primers are used at final concentrations of0.4 μM. The SMN probe is used at a final concentration of 0.15 μM. TheGAPDH primers are used at final concentrations of 0.2 μM and the probeat 0.15 μM.

The SMN2-minigene GAPDH mix (15 μL total volume) is prepared bycombining 7.5 μL of 2×RT-PCR buffer, 0.4 μL of 25×RT-PCR enzyme mix,0.75 μL of 20×GAPDH primer-probe mix, 4.0075 μL of water, 2 μL of10-fold diluted cell lysate, 0.06 μL of 100 M SMN forward primer, 0.06μL of 100 μM SMN reverse primer, and 0.225 μL of 100 μM SMN probe.

PCR is carried out at the following temperatures for the indicated time:Step 1: 48° C. (15 min); Step 2: 95° C. (10 min); Step 3: 95° C. (15sec); Step 4: 60° C. (1 min); then repeat Steps 3 and 4 for a total of40 cycles.

Each reaction mixture contains both SMN2-A minigene and GAPDHprimers/probe sets (multiplex design), allowing simultaneous measurementof the levels of two transcripts.

The increase in the abundance of the FL SMN2mini mRNA relative to thatin cells treated with vehicle control is determined from real-time PCRdata using a modified ΔΔCt method (as described in Livak and Schmittgen,Methods, 2001, 25:402-8). The amplification efficiency E is calculatedfrom the slope of the amplification curve for FL SMN2mini and GAPDHindividually. The abundance of FL SMN2mini and GAPDH mRNA are thencalculated as (1+E)^(−Ct), where Ct is the threshold value for eachamplicon. The abundance of FL SMN2mini mRNA is normalized to GAPDH mRNAabundance. The normalized FL SMN2mini mRNA abundance from testcompound-treated samples is then divided by normalized FL SMN2mini mRNAabundance from vehicle-treated cells to determine the level of FLSMN2mini mRNA relative to vehicle control.

Table 3 provides EC_(1.5x) concentrations for production of full lengthSMN2 minigene mRNA that was obtained from the 7-point concentration datagenerated according to the above procedure for particular compounds ofthe present invention.

Particular compounds of the present invention exhibit an EC_(1.5x)concentration for production of full length SMN2 minigene mRNA ≤1 μM.

More particular compounds of the present invention exhibit an EC_(1.5x)concentration for production of full length SMN2 minigene mRNA ≤0.1 μM.

Most particular compounds of the present invention exhibit an EC1.5×concentration for production of full length SMN2 minigene mRNA ≤0.02 μM.

TABLE 3 EC_(1.5x) concentrations for production of full length SMN2minigene mRNA. Example EC_(1.5x) minigene (nM) 1 3.5 2 3.8 3 3.2 4 1.8 50.6 6 2.8 7 3.7 8 0.3 9 0.1 10 6.4 11 1.4 12 1.2 13 5 14 4.1 15 4 16 1.117 6.4 18 3.6 19 10.2 20 4.3 21 9.6 22 0.9 23 3.4 24 0.4 25 0.5 26 32727 39.9 28 5 29 0.3 30 3 31 6.7 32 1.6 33 0.5 34 0.9 35 4.7 36 5 37 4.438 0.3 39 0.9

Assay 2 SMN Protein Assay in Cultured Cells

The SMN HTRF (homogeneous time resolved fluorescence) assay is used toquantify the level of SMN protein in SMA patient fibroblast cellstreated with test compounds. Materials used and respective sources arelisted below in Table 4.

TABLE 4 Materials and their respective sources used in the SMN proteinassay in cultured cells. Material Source SMA Type 1 human cells GM03813(Coriell Institute) Protease inhibitor cocktail Roche Applied ScienceCatalog No. 11836145001 Anti-SMN d2 Blue cap Cisbio Catalog No.63IDC002-SMN Anti-SMN kryptate Red cap Cisbio Catalog No. 63IDC002-SMNSMN reconstitution buffer Cisbio Catalog No. 63IDC002-SMN-Buffer DMEMLife Technologies (formerly Invitrogen) Catalog No. 11960-044 RIPA LysisBuffer 20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% ThermoScientific NP-40 Surfact-Amps Detergent Solution (Fisher Scientific,Pittsburgh/PA), 1% Sodium deoxycholate Diluent Buffer 20 mM Tris-HCl pH7.5, 150 mM NaCl Envision Plate Reader Perkin Elmer Model # 2103

Cells are thawed and cultured in DMEM-10% FBS for 72 hours. Cells aretrypsinized, counted and re-suspended to a concentration of 25,000cells/mL in DMEM-10% FBS. The cell suspensions are plated at 5,000 cellsper well in a 96 well microtiter plate and incubated for 3 to hours.Test compounds are serially diluted 3.16-fold in 100% DMSO to generate a7-point concentration curve. 1 μL of test compound solution istransferred to cell-containing wells and cells are incubated for 48hours in a cell culture incubator (37° C., 5% CO₂, 1000 relativehumidity). Triplicate samples are set up for each test compoundconcentration. After 48 hours, the supernatant is removed from the wellsand 25 μL of the RIPA lysis buffer, containing protease inhibitors, isadded to the wells and incubated with shaking at room temperature for 1hour. 25 μL of the diluent is added and then 35 μL of the resultinglysate is transferred to a 384-well plate, where each well contains 5 μLof the antibody solution (1:100 dilution of anti-SMN d2 and anti-SMNkryptate in SMN reconstitution buffer). The plate is centrifuged for 1minute to bring the solution to the bottom of the wells, then incubatedovernight at room temperature. Fluorescence for each well of the plateat 665 nm and 620 nm is measured on an EnVision multilabel plate reader(Perkin-Elmer).

The normalized fluorescence signal is calculated for each sample, Blankand vehicle control well by dividing the signal at 665 nm by the signalat 620 nm. Normalizing the signal accounts for possible fluorescencequenching due to the matrix effect of the lysate. The ΔF value (ameasurement of SMN protein abundance as a percent value) for each samplewell is calculated by subtracting the normalized average fluorescencefor the Blank control wells from the normalized fluorescence for eachsample well, then dividing this difference by the normalized averagefluorescence for the Blank control wells and multiplying the resultingvalue by 100. The ΔF value for each sample well represents the SMNprotein abundance from test compound-treated samples. The ΔF value foreach sample well is divided by the ΔF value for the vehicle controlwells to calculate the fold increase in SMN protein abundance relativeto the vehicle control. Table 5 provides EC_(1.5x) concentrations forSMN protein expression that was obtained from the 7-point concentrationdata generated according to the above procedure for particular compoundsof the present invention.

Particular compounds of the present invention exhibit an EC_(1.5x)concentration for SMN protein expression ≤1 μM.

More particular compounds of the present invention exhibit an EC_(1.5x)concentration for SMN protein expression ≤100 nM.

Most particular compounds of the present invention exhibit an EC_(1.5x)concentration for SMN protein expression ≤30 nM.

Table 6 provides the maximum fold increase of SMN protein that wasobtained from the 7-point concentration data generated according to theabove procedure for particular compounds of the present invention

Particular compounds of the present invention exhibit a maximum foldincrease >1.5.

More particular compounds of the present invention exhibit a maximumfold increase >1.7.

Most particular compounds of the present invention exhibit a maximumfold increase >1.8.

TABLE 5 EC_(1.5x) concentrations for SMN protein expression. EC1.5x SMNprotein Example (nM) 1 10.8 2 19.8 3 25.6 4 15.7 5 4.1 6 11 7 15.5 8 5.99 2.5 10 22.8 11 7 12 7.5 13 3 14 17.6 15 21.2 16 3 17 20.2 18 25 1929.8 20 37 21 68.7 22 13.8 23 23.9 24 4.7 25 11.9 26 1230 27 126.5 2849.7 29 2.1 30 13.6 31 27.7 32 4 33 4 34 4.4 35 19.5 36 34.4 37 45 383.1 39 15.8

TABLE 6 Maximum fold increase of SMN protein. max. fold Example increase1 1.84 2 1.76 3 1.81 4 1.76 5 1.71 6 1.84 7 1.76 8 1.85 9 1.92 10 1.9511 1.9 12 1.77 13 1.91 14 1.86 15 1.94 16 1.83 17 1.98 18 1.75 19 1.8320 1.72 21 1.54 22 1.69 23 1.63 24 1.77 25 1.79 26 1.52 27 1.57 28 1.7229 1.81 30 1.84 31 1.65 32 1.88 33 1.82 34 1.89 35 1.79 36 1.77 37 1.8738 1.85 39 1.81

1-56. (canceled)
 57. A method for the treatment of spinal muscularatrophy in a human in need thereof, said method comprising administeringto said human a therapeutically effective amount of

of or a pharmaceutically acceptable salt thereof.
 58. The method ofclaim 57, wherein the spinal muscular atrophy is Type 0 spinal muscularatrophy.
 59. The method of claim 57, wherein the spinal muscular atrophyis Type 1 spinal muscular atrophy.
 60. The method of claim 57, whereinthe spinal muscular atrophy is Type 2 spinal muscular atrophy.
 61. Themethod of claim 57, wherein the spinal muscular atrophy is Type 3 spinalmuscular atrophy.
 62. The method of claim 57, wherein the spinalmuscular atrophy is Type 4 spinal muscular atrophy.
 63. The method ofclaim 57, wherein the human is a human infant.
 64. The method of claim57, wherein the human is a human toddler.
 65. The method of claim 57,wherein the human is a human child.
 66. The method of claim 57, whereinthe human is a human adult.
 67. A method for the treatment of spinalmuscular atrophy in a human in need thereof, said method comprisingadministering to said human a therapeutically effective amount of


68. A method for the treatment of spinal muscular atrophy in a human inneed thereof, said method comprising administering to said human apharmaceutical composition comprising

or a pharmaceutically acceptable salt thereof, and one or morepharmaceutically acceptable excipients.
 69. The method of claim 68,wherein the spinal muscular atrophy is Type 0 spinal muscular atrophy.70. The method of claim 68, wherein the spinal muscular atrophy is Type1 spinal muscular atrophy.
 71. The method of claim 68, wherein thespinal muscular atrophy is Type 2 spinal muscular atrophy.
 72. Themethod of claim 68, wherein the spinal muscular atrophy is Type 3 spinalmuscular atrophy.
 73. The method of claim 68, wherein the spinalmuscular atrophy is Type 4 spinal muscular atrophy.
 74. The method ofclaim 68, wherein the human is a human infant.
 75. The method of claim68, wherein the human is a human toddler.
 76. The method of claim 68,wherein the human is a human child.
 77. The method of claim 68, whereinthe human is a human adult.
 78. The method of claim 68, wherein thepharmaceutical composition is administered as an oral solution.
 79. Amethod for the treatment of spinal muscular atrophy in a human in needthereof, said method comprising administering to said human apharmaceutical composition comprising

and one or more pharmaceutically acceptable excipients.
 80. A method forthe treatment of spinal muscular atrophy in a human in need thereof,said method comprising administering to said human a pharmaceuticalcomposition comprising

and one or more pharmaceutically acceptable excipients, wherein thepharmaceutical composition is administered as an oral solution.
 81. Amethod for increasing exon 7 inclusion in SMN2 messenger ribonucleicacid transcripts in a human in need thereof, said method comprisingadministering to said human a therapeutically effective amount of

or a pharmaceutically acceptable salt thereof.
 82. The method of claim81, wherein the human has spinal muscular atrophy.
 83. A method forincreasing production of SMN protein in a human in need thereof, saidmethod comprising administering to said human a therapeuticallyeffective amount of

or a pharmaceutically acceptable salt thereof.
 84. The method of claim83, wherein the human has spinal muscular atrophy.